

# SURVEY AND SUMMARY

## Matching tRNA modifications in humans to their known and predicted enzymes

Valérie de Crécy-Lagard<sup>1,2,\*</sup>, Pietro Boccaletto<sup>3</sup>, Carl G. Mangleburg<sup>1</sup>, Puneet Sharma<sup>4,5</sup>, Todd M. Lowe<sup>6,\*</sup>, Sebastian A. Leidel<sup>4,5,7,\*</sup> and Janusz M. Bujnicki<sup>3,8,\*</sup>

<sup>1</sup>Department of Microbiology and Cell Sciences, University of Florida, Gainesville, FL 32611, USA, <sup>2</sup>Cancer and Genetic Institute, University of Florida, Gainesville, FL 32611, USA, <sup>3</sup>Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology, ul. Trojdena 4, 02-109 Warsaw, Poland, <sup>4</sup>Max Planck Research Group for RNA Biology, Max Planck Institute for Molecular Biomedicine, 48149 Muenster, Germany, <sup>5</sup>Cells-in-Motion Cluster of Excellence, University of Muenster, 48149 Muenster, Germany, <sup>6</sup>Department of Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, CA 95064, USA, <sup>7</sup>Research Group for RNA Biochemistry, Institute of Chemistry and Biochemistry, University of Bern, 3012 Bern, Switzerland and <sup>8</sup>Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, ul. Umultowska 89, 61-614 Poznań, Poland

Received September 05, 2018; Revised December 28, 2018; Editorial Decision January 03, 2019; Accepted January 10, 2019

### ABSTRACT

tRNA are post-transcriptionally modified by chemical modifications that affect all aspects of tRNA biology. An increasing number of mutations underlying human genetic diseases map to genes encoding for tRNA modification enzymes. However, our knowledge on human tRNA-modification genes remains fragmentary and the most comprehensive RNA modification database currently contains information on approximately 20% of human cytosolic tRNAs, primarily based on biochemical studies. Recent high-throughput methods such as DM-tRNA-seq now allow annotation of a majority of tRNAs for six specific base modifications. Furthermore, we identified large gaps in knowledge when we predicted all cytosolic and mitochondrial human tRNA modification genes. Only 48% of the candidate cytosolic tRNA modification enzymes have been experimentally validated in mammals (either directly or in a heterologous system). Approximately 23% of the modification genes (cytosolic and mitochondrial combined) remain unknown. We discuss these ‘unidentified enzymes’

cases in detail and propose candidates whenever possible. Finally, tissue-specific expression analysis shows that modification genes are highly expressed in proliferative tissues like testis and transformed cells, but scarcely in differentiated tissues, with the exception of the cerebellum. Our work provides a comprehensive up to date compilation of human tRNA modifications and their enzymes that can be used as a resource for further studies.

### INTRODUCTION

The acquisition of post-transcriptional chemical modifications is an essential part of the maturation process required to generate functional tRNA molecules (1). Modifications have different roles in controlling stability, folding and decoding properties of tRNAs and can be determinants or anti-determinants for other components of the translation apparatus like e.g. aminoacyl-tRNA synthetases (2,3). In addition, tRNA modifications can be recognition elements of ribonucleases (4), leading to the generation of tRNA fragments that affect multiple cellular processes (5).

However, very few modifications such as m<sup>1</sup>G37, Ψ55 or t<sup>6</sup>A37 are present at a specific position of a particular tRNA

\*To whom correspondence should be addressed. Tel: +1 352 392 9416; Fax: +1 352 392 5922; Email: vcrecy@ufl.edu  
Correspondence may also be addressed to Todd Lowe. Tel: +1 831 459 1511; Email: tmjlowe@ucsc.edu  
Correspondence may also be addressed to Sebastian Leidel. Tel: +41 31 6314296; Email: sebastian.leidel@dcb.unibe.ch  
Correspondence may also be addressed to Janusz Bujnicki. Tel: +48 22 597 0750; Fax: +48 22 597 0715; Email: iamb@genesilico.pl  
Present address: Carl G. Mangleburg, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.

in (almost) all known organisms. Most of them are specific to particular taxons, from species to kingdoms. For example, lysidine (k<sup>2</sup>C34) is a hallmark of bacteria (6), while archaeosine (G<sup>+</sup>15) is only found in archaea (7). Depending on the organism, the total number of genes encoding tRNA modification enzymes varies between as little as eleven in some obligate symbionts (8) to around an estimated hundred in humans of which 50 are currently represented in MODOMICS (9).

The near complete sets of tRNA modification genes are currently available for only one organism per domain of life: *Saccharomyces cerevisiae* for eukarya, where only one gene required for the formation of ncm<sup>5</sup>U out of cm<sup>5</sup>U is missing (10), *Escherichia coli* for bacteria where only the genes for ho<sup>5</sup>U34 and Acp<sup>3</sup>U47-formation remain unidentified and *Haloferax volcanii* for archaea where a handful of genes are missing (1). Beyond these three organisms, the annotation of tRNA modification genes remains scarce, because of several issues: First, RNA modification enzymes are often part of large multifunctional protein families such as the Rossman Fold Methyltransferase (RFM) superfamily, which can act on other substrates than RNA (11). For example, some RNA methyltransferases are closely related to protein methyltransferases or DNA methyltransferases (11). Second, closely related members of orthologous families often introduce a similar chemical modification, but in different RNAs and at different positions. For example, members of the TrmFO family methylate tRNA or rRNA depending on the organism (12). Third, related enzymes can generate chemically distinct modifications. For example closely related Radical-SAM enzymes introduce methyl groups at different positions of nucleosides like in m<sup>2</sup>A or m<sup>8</sup>A (13). Finally, the same chemical modification, in particular methyl groups, can be introduced by proteins that are dissimilar (14) or even evolutionarily unrelated having arisen through non-orthologous gene displacements (15). For example, the formation of the universal m<sup>1</sup>G37 is catalyzed by TrmD and Trm5, two enzymes of completely different evolutionary origins in bacteria and in eukarya/archaea (16). The combination of these factors has made it difficult to identify enzymes responsible for many tRNA modifications and hence to determine the function of those tRNA modifications in many species including humans.

Recently, an increasing number of mutations causing genetic diseases have been mapped to human genes encoding tRNA modification enzymes (see (17–22) and Table 1), making a comprehensive list of these genes highly desirable. However, to our knowledge, no complete compilation of modifications found in both cytosolic and mitochondrial human tRNAs with their corresponding predicted or validated modification enzymes is available. For mitochondria, the best approximation is a recent list of modifications of bovine tRNAs and the predicted enzymes (23), which has been extrapolated for human tRNAs (23,24). A prediction of human tRNA methyltransferases, based on the known yeast enzymes was performed more than five years ago (25) and was recently extended to homologs of the other yeast RNA modification genes (26). Surveys of specific enzyme families such as the human m<sup>5</sup>C methyltransferases (27) or pseudouridine synthases (28) that target tRNA molecules have listed the known and missing genes for these specific

modifications. The goal of our analysis was to compile a comprehensive list of known and predicted tRNA modifications in *Homo sapiens* with genes implicated in their biosynthesis. This analysis allowed for the identification of the remaining gaps of knowledge in the field of human tRNA modifications and will help to guide future experiments. Furthermore, we have used publicly available datasets in order to determine the expression profiles and proteomic evidence of known and predicted modification enzymes. Our work will facilitate access to the current knowledge on human tRNA modification enzymes for a wider community of biologists.

## MATERIALS AND METHODS

The set of human isoacceptor tRNAs (i.e. tRNAs that are acylated with the same amino acid regardless of the anticodon sequence) was extracted from the Genomic tRNA Database (GtRNAdb): <http://gtRNadb.ucsc.edu/> (29) and is summarized here: <http://gtRNadb.ucsc.edu/genomes/eukaryota/Hsapi19/>

All modifications present in the sequences of cytosolic and mitochondrial tRNA of human (*H. sapiens*), cow (*Bos taurus*), rat (*Rattus norvegicus*), and mouse (*Mus musculus*) were extracted from the MODOMICS database of RNA modification pathways (<http://modomics.genesilico.pl/>) (9). This provided a first list that was then updated with one modification from the literature (m<sup>5</sup>C34 in Leu-CAA-tRNA) and several human modifications detected with novel tRNAseq methods (30) (m<sup>3</sup>C20 in Met-CAU-tRNA and m<sup>3</sup>C47 in Leu-CAG-tRNA and most Ser-tRNAs, m<sup>1</sup>A16 in mito-Arg-TCG-tRNA and m<sup>3</sup>C32 in mito-Thr-UGU-tRNA and mito-Ser-UGA) that were missing from MODOMICS. The MODOMICS database was updated accordingly.

High-throughput tRNA-seq modification data was derived from published study data sets (30–32). The protein and literature mining tools of NCBI (33) as well as the Uniprot resource and Id/Mapping tools (34) were used to gather data. Gene names were gathered from the HUGO Gene Nomenclature Committee (<https://www.genenames.org>) (35). Protein interaction data was derived from BioGrid (36) and the predicted mitochondrial localization from MitoCarta (<https://www.broadinstitute.org/files/shared/metabolism/mitocarta/human.mitocarta2.0.html>) (37).

Human co-expression data was extracted from the Search-based Exploration of Expression Compendium (SEEK) database (<http://seek.princeton.edu/index.jsp>) (38). Phylogenetic trees for specific protein families were extracted from PhylomeDB (<http://phylomedb.org>) (39). For gene expression analyses, RNAseq data was obtained from the GTEx portal ([www.gtexportal.org](http://www.gtexportal.org); GTEx\_Analysis\_2016-01-15\_v7\_RNASeQCv1.1.8\_gene\_tpm.gct.gz) on 30/04/2018. For each gene the transcript with the highest expression levels was selected for each tissue. Subsequently, relative expression levels were calculated and plotted as a heatmap using the heatmap.2 function in R. Tissues included in the analysis were selected to provide a general

**Table 1.** Known and predicted tRNA modification genes that have been linked to human diseases

Modification	Gene	Disease	Cyto. Pheno.	Mito. Pheno.	Article
xG	<b>THG1L</b>	Microcephaly, developmental delay, nephrotic defect	+	+	(110,175,176)
m <sup>1</sup> G	<b>TRMT10A</b>	Diabetes, intellectual disabilities, microcephaly, developmental defects	+		(111,143,177–180)
ac <sup>4</sup> C	<b>NAT10</b>	Cancer	+		(112,181,182)
ac <sup>4</sup> C	<b>THUMPDI</b>	Cancer	+		(113)
Gm	<b>TARBP1</b>	Cancer	+		(114,115)
D	<b>DUS2</b>	Cancer	+	+	(116)
Y	<b>PUS1</b>	Mitochondrial myopathy and sideroblastic anemia (MLASA)	+	+	(117,183,184)
m <sup>3</sup> C	<b>METTL6</b>	Cancer	+		(118,119)
I	<b>ADAT3</b>	Intellectual disabilities, microcephaly	+		(120,185–187)
m <sup>5</sup> C	<b>NSUN2</b>	Intellectual disabilities, developmental delay, reduced fertility, cancer	+		(121,170–172,189,229–232)
C <sub>m</sub> , U <sub>m</sub> , G <sub>m</sub> , f <sup>5</sup> C <sub>m</sub> , hm <sup>5</sup> C <sub>m</sub> , mcm <sup>5</sup> U <sub>m</sub>	<b>FTSJ1</b>	Intellectual disabilities	+		(122,123,188)
C <sub>m</sub> , G <sub>m</sub> , f <sup>5</sup> C <sub>m</sub> , hm <sup>5</sup> C <sub>m</sub>	<b>WDR6</b>	Cancer	+		(124)
Q	<b>QTRT1</b>	Cancer	+		(125)
cm <sup>5</sup> U, ncm <sup>5</sup> U, mcm <sup>5</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>ELP1</b>	Familial dysautonomia, cancer	+		(126,127,190)
cm <sup>5</sup> U, ncm <sup>5</sup> U, mcm <sup>5</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>ELP3</b>	Familial dysautonomia, Charcot–Marie–Tooth disease (CMT), cancer, amyotrophic lateral sclerosis (ALS)	+		(127,130,191,192)
cm <sup>5</sup> U, ncm <sup>5</sup> U, mcm <sup>5</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>ELP4</b>	Autism spectrum disorder, intellectual disabilities	+		(128)
cm <sup>5</sup> U, ncm <sup>5</sup> U, mcm <sup>5</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>ELP5</b>	Cancer, diabetes	+		(129,193,194)
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>CTU1</b>	Cancer	+		(127,130,131)
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>CTU2</b>	Microcephaly, nephrotic defect, cancer	+		(127,130,132,133)
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>MOCS3*</b>	Molybdenum cofactor deficiency			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>MPST*</b>	Mercaptolactate-cysteine disulfiduria (MCDU), intellectual disabilities			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>NFS1*</b>	Friedreich ataxia			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>SERGEF*</b>	Hereditary deafness, arteriosclerosis			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>CIAO1*</b>	Hereditary paraganglioma-pheochromocytoma syndromes, retinitis pigmentosa			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>NUBP1*</b>	Cancer			
s <sup>2</sup> U, mcm <sup>5</sup> s <sup>2</sup> U	<b>ISCU*</b>	Myopathy with lactic acidosis, Friedreich ataxia			
I	<b>ADAT1</b>	Coronary artery disease	+		(134)
m <sup>1</sup> G, m <sup>1</sup> I	<b>TRMT5</b>	Failure to thrive, hypertrophic cardiomyopathy, exercise intolerance	+	+	(135,136)
o <sup>2</sup> Yw, yW	<b>TRMT12</b>	Cancer			(137,138)
o <sup>2</sup> Yw, yW	<b>LCMT2</b>	Cancer	+		(139)
t <sup>6</sup> A	<b>YRDC</b>	Cancer	+		(140)
t <sup>6</sup> A	<b>OSGEP</b>	Galloway-Mowat syndrome, microcephaly, nephrotic defects	+		(18,141,195–197)
t <sup>6</sup> A	<b>TP53RK</b>	Galloway-Mowat syndrome, microcephaly, nephrotic defects, cancer	+		(141,142,195,196)
t <sup>6</sup> A	<b>TPRKB</b>	Galloway-Mowat syndrome, microcephaly, nephrotic defects	+		(141,195,196)
t <sup>6</sup> A	<b>LAGE3</b>	Galloway-Mowat syndrome, microcephaly, nephrotic defects	+		(141,195,196)
ms <sup>2</sup> t <sup>6</sup> A	<b>CDKAL1</b>	Diabetes, microcephaly, cancer	+		(144,198,199)
m <sup>5</sup> C	<b>TRDMT1</b>	Metabolism, cancer	+		(145,146)
Y	<b>PUS3</b>	Intellectual disabilities	+		(147,148)
Um	<b>TRMT44</b>	Partial Epilepsy with Pericentral Spikes (PEPS)	+		(149)
m <sup>7</sup> G	<b>METTL1</b>	Multiple sclerosis, cancer	+		(150,200,201)
m <sup>7</sup> G	<b>WDR4</b>	Microcephaly, cancer, nephrotic defects, developmental defects	+		(151,202–204)
m <sup>5</sup> U	<b>TRMT2A</b>	Cancer	+		(152)
Y	<b>PUS10</b>	Autoimmune diseases, intellectual disabilities	+		(153,205,206)
m <sup>1</sup> A	<b>TRMT6</b>	Cancer	+		(139,154,155)
m <sup>1</sup> A	<b>TRMT61A</b>	Cancer	+		(139,154,155)
m <sup>5</sup> C	<b>NSUN6*</b>	Cancer	+		(156)
m <sup>1</sup> G, m <sup>1</sup> A	<b>TRMT10C</b>	Lactic acidosis, hypotonia, feeding difficulties, deafness		+	(157,158)
m <sup>1</sup> G, m <sup>1</sup> A	<b>HSD17B10</b>	Neurodegeneration, cardiomyopathy		+	(158,207,208)
m <sup>2,2</sup> G	<b>TRMT1</b>	Intellectual disabilities, microcephaly	+	+	(159,209,210)
f <sup>5</sup> C	<b>NSUN3</b>	Cancer		+	(160,161)
tm <sup>5</sup> U	<b>GTPBP3</b>	Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), non-syndromic hearing loss	+		(162,163,211–213)
tm <sup>5</sup> U	<b>MTOI</b>	Lactic acidosis, cardiomyopathy, encephalopathy, non-syndromic hearing loss, cancer, myoclonus epilepsy associated with ragged-red fibers (MERRF)	+		(162–164,214–217)
tm <sup>5</sup> s <sup>2</sup> U	<b>TRMU</b>	Leigh syndrome, hepatopathy associated with hyperlactatemia, non-syndromic hearing loss	+		(165,218–222)
t <sup>6</sup> A	<b>OSGEP1</b>	Cancer, MERRF		+	(166,167)
i <sup>6</sup> A	<b>TRIT1</b>	Microcephaly, developmental delay, epilepsy, cancer	+	+	(168,223–225)
ms <sup>2</sup> i <sup>6</sup> A	<b>CDK5RAP1</b>	Cancer, type II diabetes, vitiligo		+	(169,226–228)
m <sup>1</sup> A	<b>TRMT61B</b>	Cancer, Alzheimer's disease		+	(173,174)

\*Disease likely caused by defects other than loss of tRNA modification.

physiological overview. Hierarchical clustering of genes was performed according to similarity of expression profile using Ward's method (40). For tissue-specific proteomics evidence, we used the human proteome map (<http://www.humanproteomemap.org/>) using the default settings (41). Proteins that were not detected in any tissue were manually removed.

## RESULTS AND DISCUSSION

### Compiling all mammalian cytosolic tRNA modifications

As a first step to predict the complete set of modification enzymes, we sought to list the nature and positions of all chemical modifications that have been identified in human cytosolic tRNAs. This task is not trivial as the set of hu-

man tRNAs used in decoding is very complex (see (42) for a recent review). Indeed, not all tRNA sequences encoded in the human genome are expressed in common cell-lines (43,44). Based on the loss of canonical secondary structure, mutations at highly conserved positions, or positioning in transcriptional silent chromosomal regions, some candidate tRNA genes are likely tRNA-derived Short Interspersed Nuclear Elements or pseudogenes, and others may have non-canonical functions outside of translation (5,45,46). Therefore, additional filtering criteria are needed to select a list of tRNAs that *most likely* decode mRNAs in the human cytosol. An updated set of 'high confidence' human tRNAs has been generated by tRNAscan-SE 2.0 (Chan, Lin and Lowe, unpublished data) and is available in the GtRNAdb (29). This list of over 400 tRNA genes contains 47 distinct isoacceptor families (including tRNA<sup>Sec</sup>, the tRNA for selenocysteine insertion).

A first set of biochemically-determined tRNA isoacceptor sequences that include chemical modifications in at least one mammal was extracted from the MODOMICS database at the time of the initial analysis (30 May 2017). Furthermore, partial information is available for modifications at specific positions such as wobble uridine (U34). It is known that 5-carbamoylmethyluridine (ncm<sup>5</sup>U) is found in Val-UAC-tRNA, 5-methoxycarbonylmethyl-2-thiouridine (mcm<sup>5</sup>s<sup>2</sup>U) in Arg-UCU-tRNA and 5-methoxycarbonylhydroxymethyluridine (mchm<sup>5</sup>U) in Gly-UCC-tRNA (47). Since the modifications of U34 in human Arg-UCU-tRNA and Gly-UCC-tRNA differ from those in the corresponding yeast tRNA, it is difficult to predict the nature of most of the U34 modifications in humans (48). Finally, a large fraction of the RNA sequence data stems from the 60s, 70s and 80s, so is based on paper and thin-layer chromatography (TLC) (49), photometric characterization of nucleosides following chromatography (50), and mass-spectrometry using low-resolution, low-sensitivity instruments (49). These methods failed to identify or distinguish some of the modifications, which are therefore listed as N and xN in Supplementary Table S1A but can now be detected with high-resolution mass spectrometry (51–54).

To add to the complexity of the task, the human genome (in contrast to yeast) encodes isoacceptor families that include many unique isodecoders, which are tRNAs with the same anticodon but contains variations in the tRNA body (42). Different isodecoders can be expressed under specific conditions as shown for the neuron-specific tRNA-Arg-UCU (55) or in the case of cancer (56). New high-throughput sequencing methods have been developed and optimized to facilitate detection of full length tRNAs such as DM-tRNA-seq (31) or tRNA-HydroSeq (57) or AlkAniline-Seq (58) and of tRNA-derived small RNAs (ARM-seq (32)). While these high-throughput RNA modification mapping methods reviewed in (59) and (30) are not yet as precise or quantitative as mass spectrometry, they do offer a practical, inexpensive method to survey a subset of modifications across all expressed tRNAs for many cell types. Using these methods also offers a first glimpse of the diversity of modification states across different isodecoders. Some isodecoder families in human such as Ala-AGC can be highly complex, contrasting the relatively simple view previously seen in budding yeast. In human, there

are 22 high confidence Ala-AGC tRNA genes detected in the genome, which encode 16 unique (by sequence) Ala-AGC tRNA transcripts; in yeast, there are 11 Ala-AGC genes, which all encode identical Ala-AGC tRNA transcripts. This variation in human tRNA sequences also leads to an apparent complexity in tRNA modifications that is only now being appreciated. For example, RNA modification data collected with traditional methods exists for just 2 out of 16 Ala-AGC isodecoders (Ala-AGC-8 and Ala-AGC-11). ARM-seq and DM-tRNA-seq, however, both detect transcripts and modifications for many more isodecoders (Supplementary Table S5). These high-throughput methods allowed to detect four human modifications that were missing in MODOMICS at the time of our first analysis (see methods section). The final count of tRNA isoacceptors with modification information is 27 in humans and 38 in mammals (Figure 1 and Supplementary Tables S1A and S5).





### Linking the modifications of human cytosolic tRNAs to their corresponding modification enzymes

We generated a current list of chemical modifications found in human cytosolic tRNAs (Figure 2A, Supplementary Table S2) by combining the modification information from the tRNA sequences compiled in Supplementary Table S1A. Subsequently, we used this list as a starting point to generate the set of predicted human tRNA modification genes.

Once the list of human cytosolic tRNA modifications had been generated (Figure 2A, Supplementary Table S2), we linked the modifications to their corresponding modification enzymes whenever possible. This was done by using the advanced query tools of Uniprot for a first pass and then surveying the literature. By default, the reference linking the gene to the function is found by accessing the Uniprot entry for a given gene. Only when the reference had not yet been captured in Uniprot (~10 cases), did we add a PMID entry in Supplementary Table S2.

Not all predictions reach the same level of credibility. For example, in some cases, experimental validation is available for the human ortholog, while in other cases only the function of the yeast ortholog is validated. Therefore, we used the following code to classify the evidence of our functional annotation: [5] *in vivo* data in mammals; [4] *in vivo* data of the human or a related mammalian enzyme in a heterologous host; [3] *in vitro* data using the human enzyme; [2] similarity to an experimentally validated gene in a non-mammalian species; [1] candidates that have not been verified in any organism; [0] no clear candidate. These predictions are available in Supplementary Table S2, and we summarized all enzymes with evidence codes 2–5 in Figure 2A, using the protein names recommended by the HUGO Gene Nomenclature committee (35). According to this assessment, we predicted at least 76 proteins to be required for the modification of cytosolic tRNAs. Clearly, this is an underestimation, as more than 24 enzymes are still unknown (evidence code 0 or 1). Furthermore, for approximately 26 proteins there is no direct *in vivo* or *in vitro* experimental data using a mammalian homolog (evidence code 2). Thus, our analysis emphasizes that extensive experimental validations and research will be required to verify specific gene predic-

		Isotype	Isoacceptor				
Ala	AGC		✓				
	TGC						
	CGC						
Arg	TCG						
	TCT	✓		✓	✓		
	CCG				✓	✓	
	CCT	✓		✓	✓	✓	
Asn	ACG				✓		
	GTT	✓	✓	✓	✓		
Asp	GTC			✓	✓	✓	
Cys	GCA						
	CTC	✓		✓			
Glu	TTC			✓			
	TTG	✓		✓			
Gln	CTG			✓	✓	✓	
	CAT	✓					
Gly	CCC	✓					
	GCC	✓					
	TCC						
His	GTG	✓					
	AAT	✓		✓			
Ile	TAT						
	GAT	✓				✓	
	TAA						
Leu	CAA	✓	✓	✓	✓		
	TAG						
	AAG				✓	✓	
	CAG	✓		✓	✓		
Lys	TTT			✓			
	CTT			✓	✓		
Met	CAT	✓		✓	✓		
Phe	GAA	✓		✓	✓		
	TGG						
Pro	AGG						
	CGG						
Sec	TCA	✓		✓	✓		
	TGA	✓					
Ser	GCT	✓		✓			
	AGA	✓		✓			
	CGA	✓					
Thr	AGT	✓		✓	✓		
	TGT	✓					
	CGT	✓					
Trp	CCA				✓	✓	
	GTA	✓		✓	✓		
Val	AAC			✓	✓		
	TAC						
	CAC						

Legend:  Homo sapiens,  Rattus norvegicus,  Mus musculus,  Bos taurus.

**Figure 1.** tRNA isoacceptors that have been biochemically characterized at the RNA level by traditional methods. Three additional tRNA isoacceptors (Rn-Val-NAC, Hs-Leu-NAA, Hs-Val-NAC) listed in Supplementary Table S1A weren't placed in this figure due to their unknown nucleotide.

tions and to identify some of the 'missing' genes. These cases will be further discussed below.

### Identifying candidates for the 'missing' genes


To identify candidates of unidentified tRNA modifications enzymes, we compiled an initial list of ~40 human proteins that are members of families known to be implicated in RNA modifications. These were mainly methyltransferases, pseudouridine synthases or THUMP-domain-containing proteins that have not yet been linked to a specific function. When we surveyed the recent literature, we found that ~2/3 of these candidates had been reported to modify rRNA or proteins. For the remaining twelve proteins/genes, we gathered localization data from Mitocarta, and analyzed co-expression using the SEEK expression database profiles to identify the candidates that are coexpressed with RNA processing or translation related genes (Supplementary Table S4). This list is far from exhaustive as new methylase folds implicated in RNA modification are still being discovered (60).

### Missing genes coding for cytosolic tRNA modification enzymes

In general, when the gene is missing, the function of the corresponding modification is very difficult to infer, as no genetic study can be conducted. In some cases, such as  $acp^3U20$ , the gene is not known in any organism, and almost no functional information is available. The only functional inference that can be done is if the gene encoding the enzyme responsible for the same modification is known in another organism. This is the case for a few modifications such as  $m^1A14$  and  $m^5U54$  in yeast or  $m^1G6$  in bacteria and archaea. Also, for complex pathways in which some genes

have already been characterized such as Q and  $mcm^5s^2U34$ , functional information is available. However, we feel it is a far stretch to transfer functional inferences made from prokaryotes or unicellular eukaryotes to human. Even if a related enzyme is known in another species, it is very difficult to predict how the unknown human enzyme discriminates substrate tRNAs from non-substrates. Thus, in the absence of information about the gene and enzyme responsible, very little information can be inferred about the function of the modification itself. Below we list modifications of human cytosolic tRNAs, for which the genes remain to be discovered and characterized, and this list also indicates the areas where functional information is missing.

- **$m^1G6/7$ :** This nucleotide is modified in multiple cytosolic and in at least one mitochondrial tRNA (Supplementary Table S1A and B). Trm14/TrmN are members of the COG0116 family of methyltransferases and target this position in several thermophilic bacteria and archaea (61). However other members of the same family, such as RmlL have been shown to methylate guanine residues in 23S RNA (62). THUMP2 and THUMP3 are two barely characterized members of this family in humans (Supplementary Table S4), and previous analyses suggested that these enzymes might be required for the formation of both cytosolic and mitochondrial modifications (23). THUMP2 was found to form a complex with the  $m^{2,2}G26$ -methylase TRMT1, while THUMP3 was shown to interact with the methylase-activator protein TRM112 (63) in two high-throughput interactome studies (36), strengthening their role as tRNA methyltransferase candidates. However, experimental verification will be required to evaluate whether these two proteins are essential for the formation of  $m^1G$ , whether they exhibit



**Figure 2.** Cloverleaf representation of tRNA, with modified positions indicated for (A) cytoplasmic and (B) mitochondrial tRNAs, respectively, indicating genes/proteins experimentally validated in human, predicted with high confidence in other species, unknown with predictions, and unknown with no predictions.

different substrates specificities towards G6 or G7 and whether they act in mitochondria or in the cytoplasm.

- **m<sup>1</sup>A14**: Enzymes responsible for this modification were identified in *S. cerevisiae* and belong to the pfam01746 family (64). The human genome encodes three members of this family: TRMT10A is required for the generation of m<sup>1</sup>G9 in cytosolic tRNAs (65). TRMT10C as part of the RNase P complex, forms m<sup>1</sup>G9 in mitochondrial tRNAs (62) and like some family members from other species, can also methylate adenosine to form m<sup>1</sup>A9 (66). Hence, TRMT10B (Supplementary Table S4) is a candidate for the elusive m<sup>1</sup>A14 methyltransferase, even if a recent report could not detect any tRNA methylation activity *in vitro* (67). As expected for a cytosolic enzyme, TRMT10B is not part of the predicted human mitoproteome (37). However, multiple reports of interactions with 25 mitochondrial ribosomal proteins (<https://thebiogrid.org/127659>) suggest this protein localizes to the mitochondria. Further experiments will be needed to determine whether TRMT10B is the missing m<sup>1</sup>A14 methyltransferase or whether TRMT10A methylates both G9 and A14 or whether a yet unknown enzyme catalyzes this reaction.
- **Acp<sup>3</sup>U20,20a**: Only very few enzymes have been characterized that modify RNA by transferring the aminocarboxypropyl (acp) group of SAM, which is the methyl donor in most RNA-methylation reactions. However, acp-transferring enzymes belong to three unrelated superfamilies, which also contain methyltransferases. The only human enzyme currently known to introduce the acp<sup>3</sup> modification is TSR3, a member of the COG2042 family (68), which is required for the biosynthesis of the hypermodified nucleotide m<sup>1</sup>acp<sup>3</sup>Ψ in 18S rRNA (69). The crystal structures of its archaeal homologs revealed that TSR3 belongs to the SPOUT class of methyltransferases (69). The second structurally characterized acp-transferase Tyw2 belongs to the unrelated RFM superfamily (70). A different acp modification has been described in the diphthamide-biosynthesis pathway, where an acp group is transferred from SAM to the carbon atom of a histidine residue of eukaryotic translation elongation factor 2 (eEF2) by an enzyme that belongs to the Radical-SAM superfamily (71). acp<sup>3</sup>U is found in several positions in tRNA of different organisms like for example acp<sup>3</sup>U47 in *E. coli* tRNA, but the corresponding enzymes have not been identified in any of these species. Since all known acp transferases most likely arose independently from methyltransferases, the acp<sup>3</sup>U-forming enzyme may currently be annotated as a hypothetical methyltransferase of unknown function (Supplementary Table S4) but it is difficult to select a plausible candidate in light of the diversity of known acp transferases.
- **Ψ**: The list of pseudouridine synthases modifying human tRNAs is far from complete. Several candidates have been proposed to be required for the modification of positions 30–32, 50, 72 or e11,12,13 (23), but several can likely be excluded as they were found to be required for the modification of mitochondrial rRNA and mito-tRNA at positions 27, 29, 39 and 50 (RPUSD4) (65,72) or mitochondrial mRNA (like RPUSD3) (73). RPUSD1 and RPUSD2 (Supplementary Table S4) have not been tested experimentally and are hence still valid candidates. Pus7/TruD, the enzyme that introduces Ψ13 is highly conserved in all three kingdoms (74) and is a member of the COG0585 family. The yeast Pus7 enzyme further modifies position 35 (75). PUS7 and PUS7L, two members of the COG0585 family in humans are products of a gene duplication that occurred most certainly in the common ancestors of metazoa (see [http://phylomedb.org/?q=search\\_tree&seqid=Q9H0K6](http://phylomedb.org/?q=search_tree&seqid=Q9H0K6)). Experiments will be required to determine whether these two enzymes have identical, overlapping or different substrates specificities. For example, one of the two enzymes might modify position 13, while the second enzyme might target position 35. Another possibility is that PUS7 and PUS7L target both positions 13 and 35, but in different tRNA isoacceptors. PUS7 is implicated in pseudouridylation of Ψ8 in tRF derived from Ala-tRNA, Cys-tRNA and Val-tRNA but whether PUS7 acts directly on tRNA has formally not been shown (76). PUS1 is multisite specific so it is a plausible candidate for the positions 30 to 32, even though it has been found that the mouse homolog modifies positions 27, 28, 34 and 36 (77). Finally, based on experimental evidence from Archaea (78), it had been postulated that the human Pus10 is required for the formation of Ψ54 (28) and this was recently experimental validated in human (79).
- **Q34**: Queuosine in position 34 (Q34) is highly conserved in bacteria and eukarya. Humans like all eukaryotes are unable to synthesize Q but instead salvage the queuine (q) base from their diet and gut microflora as a micronutrient (80). Recent studies have shown that nutritionally determined Q-tRNA levels promote Dnmt2-mediated methylation of tRNA-Asp and control translational speed of Q-decoded codons as well as at near-cognate codons (81). The heterodimeric human TGT enzyme formed by the QTRT1 and QTRT2 (previously called QTRTD1) subunits is the only fully characterized enzyme of the Q salvage pathway (80). A second human salvage-enzyme member of the DUF2419 family has been identified but its molecular function is unknown (82). Finally, the transporter for the q base or the precursor nucleoside Q is still elusive as well as the enzyme(s) that further modify the Q residue by attaching galactosyl or mannosyl moieties.
- **mcm<sup>5</sup>s<sup>2</sup>U34**: Wobble uridine is generally modified in all known organisms (see (83) for a recent review). The combination of modifications at positions 2 and 5 of the nucleobase results in an intricate tuning of codon-anticodon interactions, thus allowing the translation apparatus to distinguish codons in split-codon boxes and to introduce additional amino acids (83,84). 5-carboxymethyluridine (cm<sup>5</sup>U), the first step of the 5-modification is introduced by the action of the Elongator complex, a heteromeric complex consisting of two copies of Elp1–Elp6 that is activated by several auxiliary proteins (85). Orthologs of all yeast Elongator complex subunits are known and described in humans. However, human orthologs of the yeast regulatory components (the kinase Kti14, the phosphatase Sit4 and its regulatory subunits Sap185 and Sap190) could not be identified. Here, functional screens will be required to determine the counterparts of these components in humans. The conversion of cm<sup>5</sup>U to

mcm<sup>5</sup>U is catalyzed by the c-terminal Trm9 domain of ALKBH8 (86–88). mcm<sup>5</sup>U in some tRNA can be further hydroxylated to mchm<sup>5</sup>U by the AlkB Domain of ALKBH8 (87) or 2'-*O*-methylated to mcm<sup>5</sup>Um by an unknown enzyme. The enzyme required for ncm<sup>5</sup>U formation from cm<sup>5</sup>U is not known in any organism and remains to be identified. 2-thiolation is achieved through the action of the URM1 pathway that shares features of bacterial sulfur-carrier proteins (SCP) and ubiquitin-like proteins (UBL) (89). The URM1 pathway components are straight forward to identify. Urm1 has two homologs in humans: URM1 and MOCS2A. However, MOCS2A is required for the synthesis of the molybdopterin cofactor while URM1 is required for tRNA thiolation and MOCS3 activates the SCP of both pathways (90). The final step of the thiolation reaction is performed by a complex consisting of CTU1 and CTU2.

- **Missing methyltransferases.** Methyltransferases are the biggest group of RNA modifying enzymes. While many tRNA methyltransferases have been discovered and characterized, a few of them remain to be identified (Supplementary Table S2). Members of the NSUN family (PF01189) usually introduce m<sup>5</sup>C modifications (91) and some such as NSUN2 are multi-site specific (92). However, NSUN2 is not required for the formation of m<sup>5</sup>C40 or m<sup>5</sup>C72 (92). NSUN7 is the only member of the NSUN family without a known substrate (Supplementary Table S4). Hence, it is a strong candidate for methylating one or both these positions. However, indirect data links it to methylation of enhancer RNAs (93). Three enzymes (METTL2A, METTL2B and METTL6) have been found to be involved in m<sup>3</sup>C32 formation potentially on different tRNA targets (94). Any of these three might be required for introducing m<sup>3</sup>C at position e2 and/or 47 as the biochemical assays have been inconclusive to date (See (94), Supplementary Table S5). It is unclear, which protein synthesizes m<sup>5</sup>U54 since two human homologs of yeast Trm2 were identified: TRMT2A and TRMT2B (Supplementary Table S2). It is not known whether these two proteins catalyze the same reaction or whether they differ in substrate specificity or sub-cellular localization. For example, TRMT2B is predicted to localize to mitochondria and might be required for modifying mitochondrial tRNAs (Supplementary Table S3). Finally, no candidate can easily be proposed for the formation of m<sup>1</sup>Ψ39, Ψm39 and Gm39. The pool of methyltransferase candidates among proteins with uncharacterized functions is large (~8, Supplementary Table S4), and we did not find evidence to favor a specific candidate.

#### Identification of the genes encoding for mitochondrial tRNA modifications enzymes

The Suzuki laboratory published a thorough compilation of tRNA modification enzymes for the full set of 22 bovine mito-tRNAs (23) and most of their functional annotations can be transferred to orthologous human enzymes (Figure 2B, Supplementary Table S3). Furthermore, some open cases have been solved since. Notably, ALKBH1 and NSUN3 are required for the formation of f<sup>5</sup>C in initiator tRNA (95–97). The same ALKBH1 enzyme is further re-

quired for hm<sup>5</sup>C and f<sup>5</sup>C formation in cytosolic tRNA (95). A more complete compilation of the predicted human mitochondrial tRNA modification enzymes was published recently with extensive added functional information (24). We compiled these predictions and added evidence codes resulting in a list of 35 enzymes required to modify the full set of mitochondrial tRNAs (Figure 2B and Supplementary Table S3). An additional evidence code to classify enzymes that have been experimentally validated in the cytoplasm but not in mitochondria was added (evidence code 6). We will discuss here the remaining open questions.

The Q base is found in mitochondrial tRNAs and the catalytic subunit QTRT1 of the human transglycosylase complex is found in the mitoproteome (Supplementary Table S3). In the cytoplasm, QTRT1 forms a complex with QTRT2 (98) but it is not known whether this interaction also occurs in mitochondria. It has been shown that QTRT1 and QTRT2 are associated with the mitochondria with QTRT2 more loosely bound than QTRT1 (99). Is it possible that QTRT2 facilitates the transport of q, as the mitochondrial queuine transporter is missing?

Similar to cytosolic pseudourine synthases, the set of enzymes introducing Ψ residues in mitochondrial tRNAs is far from complete, in particular since different enzymes can introduce the same modification at a given position in different tRNAs, implying that many more might be missing. RPUSD4 was recently shown to modify 16S rRNA from mitochondria and introduce Ψ39 in mito-tRNA<sup>Phe</sup> but not in mito-tRNA<sup>Gly</sup> (72). PUS3 was predicted to modify other mitochondrial tRNAs such as mito-tRNA<sup>Gln</sup> at position 39 (23). However, experimental data on PUS3 is available only for cytosolic tRNAs, requiring additional confirmation of its mitochondrial targets. Two pseudouridine synthases without known substrates (RPUSD3 and PUS1L) localize to the mitochondria (Supplementary Table S4). RUPSD3 modifies mitochondrial mRNAs (73), leaving PUS1L as a strong candidate for an enzyme that modifies positions 30, 31, 50 and/or 57 (Supplementary Table S4). Nevertheless, we cannot exclude that a pseudouridine synthase not predicted to be mitochondrial such as RPUSD1 or RPSUD2 is actually dually-targeted as it has been recently shown for Pus10 that is translocated to the mitochondria only under specific physiological conditions (100).

In general, the situation is more complex when one gene encodes for two proteins that localize to different sub-cellular compartments, since the mitochondria-targeted isoform is often not identified as a mitochondrial protein. Thirty-seven proteins are predicted to be required for mitochondrial tRNA modifications with nine of these currently unknown, and eleven modify only mitochondrial tRNAs (Supplementary Table S3). In the Mitocarta analysis that integrates 14 different sources of predictions and experimental data to compile a list 1158 human mitochondrial protein (37), ten of these proteins were correctly identified as mitochondrial (Supplementary Table S3). The only exception is CDK5RAP1, an enzyme required for the thiolation reaction during ms<sup>2</sup>i<sup>6</sup>A formation (101,102). Of the dually targeted proteins, ten were correctly assigned as mitochondrial in Mitocarta (Supplementary Table S3) while seven others were not: TRM5, YRDC, PUS3, NSUN2,




TRM112, METTL2B and QTRT2. TRM112 and QTRT2 are non-catalytic subunits and it cannot be excluded that they are dispensable in mitochondria, as tRNA modification machineries can be simpler in mitochondria. For example, only two proteins are required for the synthesis of t<sup>6</sup>A in mitochondria while six proteins are required in the cytosol (103). The case of PUS3 has already been discussed above. For the remaining three cases, dual localization data in yeast for Sua5p (104) and for Trm5p (105) as well as predicted isoforms (see <http://www.uniprot.org/uniprot/Q08J23> for NSUN2) suggest that they can be similarly found in both compartments in humans. Hence, the MitoCarta set of mitochondrial proteins may be incomplete.

Finally, the enzymes required for the formation of m<sup>2</sup>G6, m<sup>5</sup>C72 and of several Ψ residues are experimentally uncharacterized (Supplementary Table S3). As discussed above, the two candidates for the formation of cytosolic m<sup>2</sup>G6 are THUMP2 and THUMP3. These two proteins are not predicted to localize to mitochondria (37) but this prediction might not be correct. The same is true for the candidate for the cytosolic m<sup>5</sup>C72 methylase, NSUN7.

### Tissue expression and proteomics data of tRNA modification enzymes

Disease phenotypes of aberrant tRNA modification enzymes are often linked to neuronal phenotypes, metabolic disorders and cancer (17–21). However, the tissue-specific expression profiles of tRNA modification genes have not been systematically explored. Therefore, we used expression data available through the Genotype-Tissue-Expression (GTEx) project and compared expression levels of all modification genes in representative tissues of all organs (Figure 3). We also compiled tissue-specific proteomics evidence from the human proteome map (41) (Supplementary Figure S1). Overall, there are several general trends: First, expression levels of modification genes are quite uniform between different tissues. Second, expression levels of most genes are relatively low, in particular in whole blood. Third, generally high expression levels are observed in testis and transformed cells. Fourth, expression levels in brain are below average of the tissues with the exception of the cerebellum, where expression of a small number of genes reaches levels that are similar to expression observed in testis. This is surprising given the typical neuronal phenotypes observed upon defects in human modification enzymes. There are, however, clusters of genes that are upregulated in several brain tissues (Figure 3). These findings may point to a more crucial function during early steps of differentiation and proliferation of stem cells. Thus, it is likely that many of the observed defects in humans are either developmental phenotypes or relatively subtle. Finally, even though most genes of different pathways are found in similar clusters, this is not true for all pathways, e.g. the ELP pathway. A similar trend is seen when analyzing the proteomics data (Supplementary Figure S1). With the highly expressed genes, a correlation was observed between the transcriptomic and proteomics data (for example *DUS2*, *PUS3* or *TRMT5* in testis), however, the proteomic data is less complete due to the low expression levels of most enzymes (Supplementary



**Figure 3.** Expression of tRNA modification genes and candidates in a representative set of healthy human tissues. (A) Empirically selected tissues with physiological relevance are included. (B) Like (A), but only representing a set of brain tissues. Genes are clustered according to similarity in the expression profile. Source: gtexportal.org. Genes included are from Supplementary Table S2.

Figure S1). These observations suggest that tRNA modification enzymes are able to maintain sufficiently high modification levels in differentiated tissues likely because of the high stability of tRNA and low tRNA synthesis levels. Furthermore, some modification enzymes bind to RNA that are not their natural targets (See (106–109) for specific examples). Hence, it is likely beneficial to maintain low expression levels of these enzymes to avoid unspecific modification of cellular RNA like mRNA or rRNA.

## CONCLUSIONS

This inventory of human tRNA modifications and the corresponding enzymes surprisingly reveals that despite the fact that the field of RNA modifications has dramatically expanded in recent years with 50 human modifications enzymes identified only in the last 10 years, the picture is far from complete. We estimate that between ~135 genes are required to modify cytosolic and mitochondrial tRNAs and that 23% of these genes still need to be identified and that another 22% require further experimental validations. Approximately 50% of the human modification genes have been linked to a number of human diseases (Table 1). Furthermore, all genes required for the formation of iron-sulfur clusters affect tRNA modification indirectly and are linked to diseases that are likely not mediated by tRNA modification defects. Like described before (17–22) the phenotypes are most often neurodegenerative or neurodevelopmental diseases like microcephaly and intellectual disabilities, but also renal and metabolic defects. Finally, roughly 50% of the disease genes have been linked to cancer (Table 1), suggesting that tRNA modification enzymes may provide interesting targets for cancer therapies. Also, given the wide diversity of tRNA transcript sequences in humans, the preference of different members of the modification enzyme families for different tRNA isodecoders remains an open question. An in-depth analysis of tRNA modification dynamics in various stress conditions and cell types will reveal the intimate relationship between tRNAs and their modifying partners in more detail. This compilation can act as a guide for future experiments to complete the characterization of the set of human tRNA modification enzymes.

## SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

## ACKNOWLEDGEMENTS

We thank Yuri Motorin, Jane Jackman, Marc Graille, Vincent P. Kelly, Ramesh Gupta, Peter C. Dedon and Michaela Frye for inputs and discussions, and Michaela Frye for inspiring us for Figure 1. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS.

## FUNDING

National Institutes of Health [GM70641 to V. dC.-L.; HG006753 to T.M.L.]; Max Planck Society and the European Research Council [310489-tRNAmodi to S.A.L.];

German Research Foundation [SPP 1784 to S.A.L.]; IIMCB statutory funds (to P.B. and J.M.B.); Polish National Science Centre [2012/04/A/NZ2/00455 to J.M.B.]. The open access publication charge for this paper has been waived by Oxford University Press.

*Conflict of interest statement.* Janusz M. Bujnicki is an Executive Editor of *Nucleic Acids Research*.

## REFERENCES

- El Yacoubi, B., Bailly, M. and de Crécy-Lagard, V. (2012) Biosynthesis and function of posttranscriptional modifications of transfer RNAs. *Annu. Rev. Genet.*, **46**, 69–95.
- Agris, P.F., Narendran, A., Sarachan, K., Väre, V.Y.P. and Eruysal, E. (2017) The importance of being modified: The role of RNA modifications in translational fidelity. *Enzymes*, **41**, 1–50.
- Lorenz, C., Lünse, C.E. and Mörl, M. (2017) tRNA modifications: impact on structure and thermal adaptation. *Biomolecules*, **7**, 35.
- Chanfreau, G.F. (2017) Impact of RNA modifications and RNA-modifying enzymes on eukaryotic ribonucleases. *Enzymes*, **41**, 299–329.
- Zhang, X., Cozen, A.E., Liu, Y., Chen, Q. and Lowe, T.M. (2016) Small RNA modifications: integral to function and disease. *Trends Mol. Med.*, **22**, 1025–1034.
- Suzuki, T. and Numata, T. (2014) Convergent evolution of AUA decoding in bacteria and archaea. *RNA Biol.*, **11**, 1586–1596.
- Gregson, J.M., Crain, P.F., Edmonds, C.G., Gupta, R., Hashizume, T., Phillipson, D.W. and McCloskey, J.A. (1993) Structure of the archaeal transfer RNA nucleoside G<sup>m</sup>-15 (2-amino-4,7-dihydro-4-oxo-7-beta-D-ribofuranosyl-1H-pyrrolo[2,3-d]pyrimidine-5-carboximidamide (archaeosine)). *J. Biol. Chem.*, **268**, 10076–10086.
- Gallo, L.C., Penedo, F.J., Carnethon, M., Isasi, C.R., Sotres-Alvarez, D., Malcarne, V.L., Roesch, S.C., Youngblood, M.E., Daviglius, M.L., Gonzalez, P. et al. (2014) The Hispanic Community Health Study/Study of Latinos Sociocultural Ancillary Study: sample, design, and procedures. *Ethn. Dis.*, **24**, 77–83.
- Boccalletto, P., Machnicka, M.A., Purta, E., Pitkowski, P., Baginski, B., Wirecki, T.K., de Crécy-Lagard, V., Ross, R., Limbach, P.A., Kotter, A. et al. (2018) MODOMICS: a database of RNA modification pathways. 2017 update. *Nucleic Acids Res.*, **46**, D303–D307.
- Chen, C., Huang, B., Anderson, J.T. and Byström, A.S. (2011) Unexpected accumulation of ncm(5)U and ncm(5)S(2) (U) in a trm9 mutant suggests an additional step in the synthesis of mcm(5)U and mcm(5)S(2)U. *PLoS One*, **6**, e20783.
- Bujnicki, J.M. (1999) Comparison of protein structures reveals monophyletic origin of the AdoMet-dependent methyltransferase family and mechanistic convergence rather than recent differentiation of N4-cytosine and N6-adenine DNA methylation. *Silico Biol.*, **1**, 175–182.
- Lartigue, C., Lebaudy, A., Blanchard, A., Yacoubi, B., El, Rose, S., Grosjean, H. and Douthwaite, S. (2014) The flavoprotein Mcap0476 (RlmFO) catalyzes m5U1939 modification in *Mycoplasma capricolum* 23S rRNA. *Nucleic Acids Res.*, **42**, 8073–8082.
- Yan, F. and Fujimori, D.G. (2011) RNA methylation by Radical SAM enzymes RlmN and Cfr proceeds via methylene transfer and hydride shift. *Proc. Natl. Acad. Sci. U.S.A.*, **108**, 3930–3934.
- Husain, N., Tkaczuk, K.L., Tulsidas, S.R., Kaminska, K.H., Čubrilo, S., Maravić-Vlahovićek, G., Bujnicki, J.M. and Sivaraman, J. (2010) Structural basis for the methylation of G1405 in 16S rRNA by aminoglycoside resistance methyltransferase Sgm from an antibiotic producer: a diversity of active sites in m7G methyltransferases. *Nucleic Acids Res.*, **38**, 4120–4132.
- Kozbial, P.Z. and Mushegian, A.R. (2005) Natural history of S-adenosylmethionine-binding proteins. *BMC Struct. Biol.*, **5**, 19.
- Goto-Ito, S., Ito, T. and Yokoyama, S. (2017) Trm5 and trmd: two enzymes from distinct origins catalyze the identical tRNA modification, m1g37. *Biomolecules*, **7**, 32.
- Torres, A.G., Batlle, E. and Ribas de Pouplana, L. (2014) Role of tRNA modifications in human diseases. *Trends Mol. Med.*, **20**, 306–314.

18. Edvardson, S., Prunetti, L., Arraf, A., Haas, D., Bacusmo, J.M., Hu, J.F., Ta-Shma, A., Dedon, P.C., de Crécy-Lagard, V. and Elpeleg, O. (2017) tRNA N6-adenosine threonylcarbamoyltransferase defect due to KAE1/TCS3 (OSGEP) mutation manifest by neurodegeneration and renal tubulopathy. *Eur. J. Hum. Genet.*, **25**, 545–551.
19. Bednářová, A., Hanna, M., Durham, I., VanCleave, T., England, A., Chaudhuri, A. and Krishnan, N. (2017) Lost in translation: defects in transfer RNA modifications and neurological disorders. *Front. Mol. Neurosci.*, **10**, 135.
20. Sarin, L.P. and Leidel, S.A. (2014) Modify or die? - RNA modification defects in metazoans. *RNA Biol.*, **11**, 1555–1567.
21. Jonkhout, N., Tran, J., Smith, M.A., Schonrock, N., Mattick, J.S. and Novoa, E.M. (2017) The RNA modification landscape in human disease. *RNA*, **23**, 1754–1769.
22. Pereira, M., Francisco, S., Varanda, A.S., Santos, M., Santos, M.A.S. and Soares, A.R. (2018) Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease. *Int. J. Mol. Sci.*, **19**, 3738.
23. Suzuki, T. and Suzuki, T. (2014) A complete landscape of post-transcriptional modifications in mammalian mitochondrial tRNAs. *Nucleic Acids Res.*, **42**, 7346–7357.
24. Bohnsack, M.T. and Sloan, K.E. (2018) The mitochondrial epitranscriptome: the roles of RNA modifications in mitochondrial translation and human disease. *Cell. Mol. Life Sci.*, **75**, 241–260.
25. Towns, W.L. and Begley, T.J. (2012) Transfer RNA Methyltransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health. *DNA Cell Biol.*, **31**, 434–454.
26. Maraia, R.J. and Arimbasseri, A.G. (2017) Factors that shape eukaryotic tRNAomes: Processing, modification and anticodon-codon use. *Biomolecules*, **7**, 26.
27. Popis, M.C., Blanco, S. and Frye, M. (2016) Posttranscriptional methylation of transfer and ribosomal RNA in stress response pathways, cell differentiation, and cancer. *Curr. Opin. Oncol.*, **28**, 65–71.
28. Spenkuch, F., Motorin, Y. and Helm, M. (2014) Pseudouridine: still mysterious, but never a fake (uridine)! *RNA Biol.*, **11**, 1540–1554.
29. Chan, P.P. and Lowe, T.M. (2016) GtRNAdb 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes. *Nucleic Acids Res.*, **44**, D184–D189.
30. Clark, W.C., Evans, M.E., Dominissini, D., Zheng, G. and Pan, T. (2016) tRNA base methylation identification and quantification via high-throughput sequencing. *RNA*, **22**, 1771–1784.
31. Zheng, G., Qin, Y., Clark, W.C., Dai, Q., Yi, C., He, C., Lambowitz, A.M. and Pan, T. (2015) Efficient and quantitative high-throughput tRNA sequencing. *Nat. Methods*, **12**, 835–837.
32. Cozen, A.E., Quartley, E., Holmes, A.D., Hrabeta-Robinson, E., Phizicky, E.M. and Lowe, T.M. (2015) ARM-seq: AlkB-facilitated RNA methylation sequencing reveals a complex landscape of modified tRNA fragments. *Nat. Methods*, **12**, 879–884.
33. Agarwala, R., Barrett, T., Beck, J., Benson, D.A., Bollin, C., Bolton, E., Bourexis, D., Brister, J.R., Bryant, S.H., Canese, K. et al. (2016) Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.*, **44**, D7–D19.
34. Bateman, A., Martin, M.J., O'Donovan, C., Magrane, M., Apweiler, R., Alpi, E., Antunes, R., Arganiska, J., Bely, B., Bingley, M. et al. (2015) UniProt: a hub for protein information. *Nucleic Acids Res.*, **43**, D204–D212.
35. Gray, K.A., Yates, B., Seal, R.L., Wright, M.W. and Bruford, E.A. (2015) Genenames.org: the HGNC resources in 2015. *Nucleic Acids Res.*, **43**, D1079–D1085.
36. Chatr-Aryamontri, A., Oughtred, R., Boucher, L., Rust, J., Chang, C., Kolas, N.K., O'Donnell, L., Oster, S., Theesfeld, C., Sellam, A. et al. (2017) The BioGRID interaction database: 2017 update. *Nucleic Acids Res.*, **45**, D369–D379.
37. Calvo, S.E., Clauser, K.R. and Mootha, V.K. (2016) MitoCarta2.0: An updated inventory of mammalian mitochondrial proteins. *Nucleic Acids Res.*, **44**, D1251–D1257.
38. Zhu, Q., Wong, A.K., Krishnan, A., Aure, M.R., Tadych, A., Zhang, R., Corney, D.C., Greene, C.S., Bongo, L.A., Kristensen, V.N. et al. (2015) Targeted exploration and analysis of large cross-platform human transcriptomic compendia. *Nat. Methods*, **12**, 211–214.
39. Huerta-Cepas, J., Capella-Gutiérrez, S., Pryszcz, L.P., Marcet-Houben, M. and Gabaldón, T. (2014) PhylomeDB v4: zooming into the plurality of evolutionary histories of a genome. *Nucleic Acids Res.*, **42**, D897–D902.
40. Ward, J.H. (1963) Hierarchical grouping to optimize an objective function. *J. Am. Stat. Assoc.*, **58**, 236–244.
41. Kim, M.-S., Pinto, S.M., Getnet, D., Nirujogi, R.S., Manda, S.S., Chaerkady, R., Madugundu, A.K., Kelkar, D.S., Isserlin, R., Jain, S. et al. (2014) A draft map of the human proteome. *Nature*, **509**, 575–581.
42. Schimmel, P. (2018) RNA Processing and Modifications: The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. *Nat. Rev. Mol. Cell Biol.*, **19**, 45–58.
43. Barski, A., Chepelev, I., Liko, D., Cuddapah, S., Fleming, A.B., Birch, J., Cui, K., White, R.J. and Zhao, K. (2010) Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes. *Nat. Struct. Mol. Biol.*, **17**, 629–634.
44. Canella, D., Praz, V., Reina, J.H., Cousin, P. and Hernandez, N. (2010) Defining the RNA polymerase III transcriptome: genome-wide localization of the RNA polymerase III transcription machinery in human cells. *Genome Res.*, **20**, 710–721.
45. Martinez, G., Choudury, S.G. and Slotkin, R.K. (2017) tRNA-derived small RNAs target transposable element transcripts. *Nucleic Acids Res.*, **45**, 5142–5152.
46. Goodarzi, H., Liu, X., Nguyen, H.C.B., Zhang, S., Fish, L. and Tavazoie, S.F. (2015) Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. *Cell*, **161**, 790–802.
47. Yoshida, M., Kataoka, N., Miyauchi, K., Ohe, K., Iida, K., Yoshida, S., Nojima, T., Okuno, Y., Onogi, H., Usui, T. et al. (2015) Rectifier of aberrant mRNA splicing recovers tRNA modification in familial dysautonomia. *Proc. Natl. Acad. Sci. U.S.A.*, **112**, 2764–2769.
48. Johansson, M.J.O., Esberg, A., Huang, B., Björk, G.R. and Byström, A.S. (2008) Eukaryotic wobble uridine modifications promote a functionally redundant decoding system. *Mol. Cell Biol.*, **28**, 3301–3312.
49. Harada, F., Gross, H.J., Kimura, F., Chang, S.H., Nishimura, S. and RajBhandary, U.L. (1968) 2-Methylthio N6-( $\Delta^2$ -isopentenyl) adenosine: a component of *E. coli* tyrosine transfer RNA. *Biochem. Biophys. Res. Commun.*, **33**, 299–306.
50. Gehrke, C.W., Kuo, K.C. and Zumwalt, R.W. (1980) Chromatography of nucleosides. *J. Chromatogr. A*, **188**, 129–147.
51. Wagner, T.M., Nair, V., Guymon, R., Pomerantz, S.C., Crain, P.F., Davis, D.R. and McCloskey, J.A. (2004) A novel method for sequence placement of modified nucleotides in mixtures of transfer RNA. *Nucleic Acids Symp. Ser. (Oxf.)*, **48**, 263–264.
52. Meng, Z. and Limbach, P.A. (2006) Mass spectrometry of RNA: linking the genome to the proteome. *Brief. Funct. Genomics*, **5**, 87–95.
53. Suzuki, T., Ikeuchi, Y., Noma, A., Suzuki, T. and Sakaguchi, Y. (2007) Mass spectrometric identification and characterization of RNA-modifying enzymes. *Methods Enzymol.*, **425**, 211–229.
54. Cai, W.M., Chionh, Y.H., Hia, F., Gu, C., Kellner, S., McBee, M.E., Ng, C.S., Pang, Y.L.J., Prestwich, E.G., Lim, K.S. et al. (2015) A platform for discovery and quantification of modified ribonucleosides in RNA: application to stress-induced reprogramming of tRNA modifications. *Methods Enzymol.*, **560**, 29–71.
55. Ishimura, R., Nagy, G., Dotu, I., Zhou, H., Yang, X., Senju, S., Nishimura, Y., Chuang, J.H. and Ackerman, S.L. (2014) Ribosome stalling induced by mutation of a CNS-specific tRNA causes neurodegeneration. *Science*, **345**, 455–459.
56. Pavon-Eternod, M., Gomes, S., Geslain, R., Dai, Q., Rosner, M.R. and Pan, T. (2009) tRNA over-expression in breast cancer and functional consequences. *Nucleic Acids Res.*, **37**, 7268–7280.
57. Gogakos, T., Brown, M., Garzia, A., Meyer, C., Hafner, M. and Tuschl, T. (2017) Characterizing expression and processing of precursor and mature human tRNAs by hydro-tRNAseq and PAR-CLIP. *Cell Rep.*, **20**, 1463–1475.
58. Marchand, V., Ayadi, L., Ernst, F.G.M., Hertler, J., Bourguignon-Igel, V., Galvanin, A., Kotter, A., Helm, M., Lafontaine, D.L.J. and Motorin, Y. (2018) AlkAniline-Seq: profiling of m7G and m3C RNA modifications at single nucleotide resolution. *Angew. Chem. Int. Ed. Engl.*, **57**, 16785–16790.

59. Limbach,P.A. and Paulines,M.J. (2017) Going global: the new era of mapping modifications in RNA. *Wiley Interdiscip. Rev. RNA*, **8**, e1367.
60. Kimura,S., Miyauchi,K., Ikeuchi,Y., Thiaville,P.C., de Crécy-Lagard,V. and Suzuki,T. (2014) Discovery of the  $\beta$ -barrel-type RNA methyltransferase responsible for N6-methylation of N6-threonylcarbamoyladenine in tRNAs. *Nucleic Acids Res.*, **42**, 9350–9365.
61. Fislage,M., Roovers,M., Tuszyńska,I., Bujnicki,J.M., Droogmans,L. and Versées,W. (2012) Crystal structures of the tRNA:m2G6 methyltransferase Trm14/TrmN from two domains of life. *Nucleic Acids Res.*, **40**, 5149–5161.
62. Sergiev,P. V., Bogdanov,A.A. and Dontsova,O.A. (2007) Ribosomal RNA guanine-(N2)-methyltransferases and their targets. *Nucleic Acids Res.*, **35**, 2295–2301.
63. Bourgeois,G., Létourneau,J., van Tran,N. and Graille,M. (2017) Trm112, a protein activator of methyltransferases modifying actors of the eukaryotic translational apparatus. *Biomolecules*, **7**, E7.
64. Jackman,J.E., Montange,R.K., Malik,H.S. and Phizicky,E.M. (2003) Identification of the yeast gene encoding the tRNA m1G methyltransferase responsible for modification at position 9. *RNA*, **9**, 574–585.
65. Evans,D.G., Harkness,E., Laloo,F. and Howell,A. (2014) Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies. *J. Med. Genet.*, **51**, 573–580.
66. Van Laer,B., Roovers,M., Wauters,L., Kasprzak,J.M., Dyzma,M., Deyaert,E., Singh,R.K., Feller,A., Bujnicki,J.M., Droogmans,L. et al. (2016) Structural and functional insights into tRNA binding and adenosine N1-methylation by an archaeal Trm10 homologue. *Nucleic Acids Res.*, **44**, 940–953.
67. Vilardo,E., Nachbagauer,C., Buzet,A., Taschner,A., Holzmann,J. and Rossmann,W. (2018) A subcomplex of human mitochondrial RNase P is a bifunctional methyltransferase - extensive moonlighting in mitochondrial tRNA biogenesis. *Nucleic Acids Res.*, **46**, 11126–11127.
68. Armengaud,J., Dedieu,A., Solques,O., Pellequer,J.L. and Quemener,E. (2005) Deciphering structure and topology of conserved COG2042 orphan proteins. *BMC Struct. Biol.*, **5**, 3.
69. Meyer,B., Wurm,J.P., Sharma,S., Immer,C., Pogoryelov,D., Kötter,P., Lafontaine,D.L.J., Wöhnert,J. and Entian,K.D. (2016) Ribosome biogenesis factor Tsr3 is the aminocarboxypropyl transferase responsible for 18S rRNA hypermodification in yeast and humans. *Nucleic Acids Res.*, **44**, 4304–4316.
70. Umitsu,M., Nishimasu,H., Noma,A., Suzuki,T., Ishitani,R. and Nureki,O. (2009) Structural basis of AdoMet-dependent aminocarboxypropyl transfer reaction catalyzed by tRNA-wybutosine synthesizing enzyme, TYW2. *Proc. Natl. Acad. Sci. U.S.A.*, **106**, 15616–15621.
71. Schaffrath,R., Abdel-Fattah,W., Klassen,R. and Stark,M.J.R. (2014) The diphthamide modification pathway from *Saccharomyces cerevisiae* - revisited. *Mol. Microbiol.*, **94**, 1213–1226.
72. Zaganelli,S., Rebelo-Guimar,P., Maundrell,K., Rozanska,A., Pierredon,S., Powell,C.A., Jourdain,A.A., Hulo,N., Lightowers,R.N., Chrzanowska-Lightowers,Z.M. et al. (2017) The pseudouridine synthase RPUSD4 is an essential component of mitochondrial RNA granules. *J. Biol. Chem.*, **292**, 4519–4532.
73. Antonicka,H., Choquet,K., Lin,Z., Gingras,A., Kleinman,C.L. and Shoubridge,E.A. (2017) A pseudouridine synthase module is essential for mitochondrial protein synthesis and cell viability. *EMBO Rep.*, **18**, 28–38.
74. Kaya,Y. and Ofengand,J. (2003) A novel unanticipated type of pseudouridine synthase with homologs in bacteria, archaea, and eukarya. *RNA*, **9**, 711–721.
75. Urban,A., Behm-Ansmant,I., Branlant,C. and Motorin,Y. (2009) RNA sequence and two-dimensional structure features required for efficient substrate modification by the *Saccharomyces cerevisiae* RNA: $\Psi$ -synthase Pus7p. *J. Biol. Chem.*, **284**, 5845–5858.
76. Guzzi,N., Cieřla,M., Ngoc,P.C.T., Lang,S., Arora,S., Dimitriou,M., Pimková,K., Sommarin,M.N.E., Munita,R., Lubas,M. et al. (2018) Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. *Cell*, **173**, 1204–1216.
77. Behm-Ansmant,I., Massenot,S., Immel,F., Patton,J.R., Motorin,Y. and Branlant,C. (2006) A previously unidentified activity of yeast and mouse RNA: pseudouridine synthases 1 (Pus1p) on tRNAs. *RNA*, **12**, 1583–1593.
78. Joardar,A., Jana,S., Fitzek,E., Gurha,P., Majumder,M., Chatterjee,K., Geisler,M. and Gupta,R. (2013) Role of forefinger and thumb loops in production of  $\Psi$ 54 and  $\Psi$ 55 in tRNAs by archaeal Pus10. *RNA*, **19**, 1279–1294.
79. Deogharia,M., Mukhopadhyay,S., Joardar,A. and Gupta,R. (2018) The human ortholog of archaeal Pus10 produces pseudouridine 54 in select tRNAs where its recognition sequence contains a modified residue. *RNA*, doi:10.1261/rna.068114.118.
80. Fergus,C., Barnes,D., Alqasem,M.A. and Kelly,V.P. (2015) The queuine micronutrient: charting a course from microbe to man. *Nutrients*, **7**, 2897–2929.
81. Tuorto,F., Legrand,C., Cirzi,C., Federico,G., Liebers,R., Müller,M., Ehrenhofer-Murray,A.E., Dittmar,G., Gröne,H.-J. and Lyko,F. (2018) Queuosine-modified tRNAs confer nutritional control of protein translation. *EMBO J.*, **37**, e99777.
82. Zailot,R., Brochier-Armanet,C., Gaston,K.W., Forouhar,F., Limbach,P.A., Hunt,J.F. and de Crécy-Lagard,V. (2014) Plant, animal, and fungal micronutrient queuosine is salvaged by members of the DUF2419 protein family. *ACS Chem. Biol.*, **9**, 1812–1825.
83. Schaffrath,R. and Leidel,S.A. (2017) Wobble uridine modifications—a reason to live, a reason to die?! *RNA Biol.*, **14**, 1209–1222.
84. Grosjean,H. and Westhof,E. (2016) An integrated, structure- and energy-based view of the genetic code. *Nucleic Acids Res.*, **44**, 8020–8040.
85. Dauden,M.I., Jaciuk,M., Müller,C.W. and Glatt,S. (2018) Structural asymmetry in the eukaryotic Elongator complex. *FEBS Lett.*, **592**, 502–515.
86. Fu,D., Brophy,J.A.N., Chan,C.T.Y., Atmore,K.A., Begley,U., Paules,R.S., Dedon,P.C., Begley,T.J. and Samson,L.D. (2010) Human AlkB homolog ABH8 is a tRNA methyltransferase required for wobble uridine modification and DNA damage survival. *Mol. Cell. Biol.*, **30**, 2449–2459.
87. Fu,Y., Dai,Q., Zhang,W., Ren,J., Pan,T. and He,C. (2010) The AlkB domain of mammalian ABH8 catalyzes hydroxylation of 5-methoxycarbonylmethyluridine at the wobble position of tRNA. *Angew. Chem. Int. Ed. Engl.*, **49**, 8885–8888.
88. Songe-Møller,L., van den Born,E., Leihne,V., Vågbo,C.B., Kristoffersen,T., Krokan,H.E., Kirpekar,F., Falnes,P.Ø. and Klungland,A. (2010) Mammalian ALKBH8 possesses tRNA methyltransferase activity required for the biogenesis of multiple wobble uridine modifications implicated in translational decoding. *Mol. Cell. Biol.*, **30**, 1814–1827.
89. Termathe,M. and Leidel,S.A. (2018) The Uba4 domain interplay is mediated via a thioester that is critical for tRNA thiolation through Urm1 thiocarboxylation. *Nucleic Acids Res.*, **46**, 5171–5181.
90. Chowdhury,M.M., Dosche,C., Löhmansröben,H.-G. and Leimkühler,S. (2012) Dual role of the molybdenum cofactor biosynthesis protein MOCS3 in tRNA thiolation and molybdenum cofactor biosynthesis in humans. *J. Biol. Chem.*, **287**, 17297–17307.
91. Bujnicki,J.M., Feder,M., Ayres,C.L. and Redman,K.L. (2004) Sequence-structure-function studies of tRNA:m5C methyltransferase Trm4p and its relationship to DNA:m5C and RNA:m5U methyltransferases. *Nucleic Acids Res.*, **32**, 2453–2463.
92. Auxilien,S., Guérineau,V., Szwejkowska-Kulińska,Z. and Golinelli-Pimpaneau,B. (2012) The human tRNA m5C methyltransferase Misu is multisite-specific. *RNA Biol.*, **9**, 1331–1338.
93. Aguilo,F., Li,S. De, Balasubramanian,N., Sancho,A., Benko,S., Zhang,F., Vashisht,A., Rengasamy,M., Andino,B., Chen,C. Hung et al. (2016) Deposition of 5-methylcytosine on enhancer RNAs enables the coactivator function of PGC-1 $\alpha$ . *Cell Rep.*, **14**, 479–492.
94. Xu,L., Liu,X., Sheng,N., Oo,K.S., Liang,J., Chionh,Y.H., Xu,J., Ye,F., Gao,Y.-G., Dedon,P.C. et al. (2017) Three distinct 3-methylcytidine (m3C) methyltransferases modify tRNA and mRNA in mice and humans. *J. Biol. Chem.*, **292**, 14695–14703.
95. Kawarada,L., Suzuki,T., Ohira,T., Hirata,S., Miyauchi,K. and Suzuki,T. (2017) ALKBH1 is an RNA dioxygenase responsible for cytoplasmic and mitochondrial tRNA modifications. *Nucleic Acids Res.*, **45**, 7401–7415.
96. Haag,S., Sloan,K.E., Ranjan,N., Warda,A.S., Kretschmer,J., Blessing,C., Hübner,B., Seikowski,J., Dennerlein,S., Rehling,P. et al.

- (2016) NSUN3 and ABH1 modify the wobble position of mt-tRNA<sup>Met</sup> to expand codon recognition in mitochondrial translation. *EMBO J.*, **35**, 2104–2119.
97. Van Haute, L., Dietmann, S., Kremer, L., Hussain, S., Pearce, S.F., Powell, C.A., Rorbach, J., Lantaff, R., Blanco, S., Sauer, S. *et al.* (2016) Deficient methylation and formylation of mt-tRNA<sup>Met</sup>wobble cytosine in a patient carrying mutations in NSUN3. *Nat. Commun.*, **7**, 12039.
98. Chen, Y.C., Kelly, V.P., Stachura, S. V. and Garcia, G.A. (2010) Characterization of the human tRNA-guanine transglycosylase: confirmation of the heterodimeric subunit structure. *RNA*, **16**, 958–968.
99. Boland, C., Hayes, P., Santa-Maria, I., Nishimura, S. and Kelly, V.P. (2009) Queuosine formation in eukaryotic tRNA occurs via a mitochondria-localized heteromeric transglycosylase. *J. Biol. Chem.*, **284**, 18218–18227.
100. Jana, S., Hsieh, A.C. and Gupta, R. (2017) Reciprocal amplification of caspase-3 activity by nuclear export of a putative human RNA-modifying protein, PUS10 during TRAIL-induced apoptosis. *Cell Death Dis.*, **8**, e3093.
101. Wei, F.Y., Zhou, B., Suzuki, T., Miyata, K., Ujihara, Y., Horiguchi, H., Takahashi, N., Xie, P., Michiue, H., Fujimura, A. *et al.* (2015) Cdk5rap1-mediated 2-methylthio modification of mitochondrial tRNAs governs protein translation and contributes to myopathy in mice and humans. *Cell Metab.*, **21**, 428–442.
102. Fakruddin, M., Wei, F.Y., Emura, S., Matsuda, S., Yasukawa, T., Kang, D. and Tomizawa, K. (2017) Cdk5rap1-mediated 2-methylthio-N6-isopentenyladenosine modification is absent from nuclear-derived RNA species. *Nucleic Acids Res.*, **45**, 11954–11961.
103. Thiaville, P.C., Iwata-Reuyl, D. and DeCrécy-Lagard, V. (2014) Diversity of the biosynthesis pathway for threonylcarbamoyladenine (t6A), a universal modification of tRNA. *RNA Biol.*, **11**, 1529–1539.
104. Thiaville, P.C., Yacoubi, B. El, Perrochia, L., Hecker, A., Prigent, M., Thiaville, J.J., Forterre, P., Namy, O., Basta, T. and de Crécy-Lagard, V. (2014) Cross kingdom functional conservation of the core universally conserved threonylcarbamoyladenine tRNA synthesis enzymes. *Eukaryot. Cell*, **13**, 1222–1231.
105. Lee, C., Kramer, G., Graham, D.E. and Appling, D.R. (2007) Yeast mitochondrial initiator tRNA is methylated at guanosine 37 by the Trm5-encoded tRNA (guanine-N1)-methyltransferase. *J. Biol. Chem.*, **282**, 27744–27753.
106. Leidel, S., Pedrioli, P.G.A., Bucher, T., Brost, R., Costanzo, M., Schmidt, A., Aebersold, R., Boone, C., Hofmann, K. and Peter, M. (2009) Ubiquitin-related modifier Urm1 acts as a sulphur carrier in thiolation of eukaryotic transfer RNA. *Nature*, **458**, 228–232.
107. Waller, T.J., Read, D.F., Engelke, D.R. and Smaldino, P.J. (2017) The human tRNA-modifying protein, TRIT1, forms amyloid fibers in vitro. *Gene*, **612**, 19–24.
108. Pratt-Hyatt, M., Pai, D.A., Haeusler, R.A., Wozniak, G.G., Good, P.D., Miller, E.L., McLeod, I.X., Yates, J.R., Hopper, A.K. and Engelke, D.R. (2013) Mod5 protein binds to tRNA gene complexes and affects local transcriptional silencing. *Proc. Natl. Acad. Sci. U.S.A.*, **110**, E3081–E3089.
109. Keffer-Wilkes, L.C., Veerareddygar, G.R. and Kothe, U. (2016) RNA modification enzyme TruB is a tRNA chaperone. *Proc. Natl. Acad. Sci. U.S.A.*, **113**, 14306–14311.
110. Murphy, M., Docherty, N.G., Griffin, B., Howlin, J., McArdle, E., McMahon, R., Schmid, H., Kretzler, M., Droguett, A., Mezzano, S. *et al.* (2008) IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. *J. Am. Soc. Nephrol.*, **19**, 1672–1680.
111. Cosentino, C., Toivonen, S., Diaz Villamil, E., Atta, M., Ravanat, J.-L., Demine, S., Schiavo, A.A., Pachera, N., Deglasse, J.-P., Jonas, J.-C. *et al.* (2018) Pancreatic beta-cell tRNA hypomethylation and fragmentation link TRMT10A deficiency with diabetes. *Nucleic Acids Res.*, **46**, 10302–10318.
112. Zhang, H., Hou, W., Wang, H.-L., Liu, H.-J., Jia, X.-Y., Zheng, X.-Z., Zou, Y.-X., Li, X., Hou, L., McNutt, M.A. *et al.* (2014) GSK-3β-regulated N-acetyltransferase 10 is involved in colorectal cancer invasion. *Clin. Cancer Res.*, **20**, 4717–4729.
113. Zhang, X., Jiang, G., Sun, M., Zhou, H., Miao, Y., Liang, M., Wang, E. and Zhang, Y. (2017) Cytosolic THUMP1 promotes breast cancer cells invasion and metastasis via the AKT-GSK3-Snail pathway. *Oncotarget*, **8**, 13357–13366.
114. Ye, J., Wang, J., Zhang, N., Liu, Y., Tan, L. and Xu, L. (2018) Expression of TARBP1 protein in human non-small-cell lung cancer and its prognostic significance. *Oncol. Lett.*, **15**, 7182–7190.
115. Sand, M., Skrygan, M., Georgas, D., Arenz, C., Gambichler, T., Sand, D., Altmeyer, P. and Bechara, F.G. (2012) Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex (RISC) components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer. *Mol. Carcinog.*, **51**, 916–922.
116. Kato, T., Daigo, Y., Hayama, S., Ishikawa, N., Yamabuki, T., Ito, T., Miyamoto, M., Kondo, S. and Nakamura, Y. (2005) A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis. *Cancer Res.*, **65**, 5638–5646.
117. Bykhovskaya, Y., Casas, K., Mengesha, E., Inbal, A. and Fischel-Ghodsian, N. (2004) Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). *Am. J. Hum. Genet.*, **74**, 1303–1308.
118. Gatz, M.L., Silva, G.O., Parker, J.S., Fan, C. and Perou, C.M. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat. Genet.*, **46**, 1051–1059.
119. Tan, X.-L., Moyer, A.M., Fridley, B.L., Schaid, D.J., Niu, N., Batzler, A.J., Jenkins, G.D., Abo, R.P., Li, L., Cunningham, J.M. *et al.* (2011) Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. *Clin. Cancer Res.*, **17**, 5801–5811.
120. Alazami, A.M., Hijazi, H., Al-Dosari, M.S., Shaheen, R., Hashem, A., Aldahmesh, M.A., Mohamed, J.Y., Kentab, A., Salih, M.A., Awaji, A. *et al.* (2013) Mutation in ADAT3, encoding adenosine deaminase acting on transfer RNA, causes intellectual disability and strabismus. *J. Med. Genet.*, **50**, 425–430.
121. Frye, M. and Watt, F.M. (2006) The RNA methyltransferase Misu (NSun2) mediates Myc-induced proliferation and is upregulated in tumors. *Curr. Biol.*, **16**, 971–981.
122. Guy, M.P., Shaw, M., Weiner, C.L., Hobson, L., Stark, Z., Rose, K., Kalscheuer, V.M., Gecz, J. and Phizicky, E.M. (2015) Defects in tRNA anticodon loop 2'-O-methylation are implicated in nonsyndromic X-linked intellectual disability due to mutations in FTSJ1. *Hum. Mutat.*, **36**, 1176–1187.
123. Wang, R., Lei, T., Fu, F., Li, R., Jing, X., Yang, X., Liu, J., Li, D. and Liao, C. (2018) Application of chromosome microarray analysis in patients with unexplained developmental delay/intellectual disability in South China. *Pediatr. Neonatol.*, **S1875-9572**, 30317–30320.
124. Xie, X., Wang, Z. and Chen, Y. (2007) Association of LKB1 with a WD-repeat protein WDR6 is implicated in cell growth arrest and p27(Kip1) induction. *Mol. Cell Biochem.*, **301**, 115–122.
125. Gündüz, U., Elliott, M.S., Seubert, P.H., Houghton, J.A., Houghton, P.J., Trewyn, R.W. and Katze, J.R. (1992) Absence of tRNA-guanine transglycosylase in a human colon adenocarcinoma cell line. *Biochim. Biophys. Acta*, **1139**, 229–238.
126. Slaugenhaupt, S.A., Blumenfeld, A., Gill, S.P., Leyne, M., Mull, J., Cuajungco, M.P., Liebert, C.B., Chadwick, B., Idelson, M., Reznik, L. *et al.* (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. *Am. J. Hum. Genet.*, **68**, 598–605.
127. Rapino, F., Delaunay, S., Rambow, F., Zhou, Z., Tharun, L., De Tullio, P., Sin, O., Shostak, K., Schmitz, S., Piepers, J. *et al.* (2018) Codon-specific translation reprogramming promotes resistance to targeted therapy. *Nature*, **558**, 605–609.
128. Addis, L., Ahn, J.W., Dobson, R., Dixit, A., Ogilvie, C.M., Pinto, D., Vaas, A.K., Coon, H., Chaste, P., Wilson, S. *et al.* (2015) Microdeletions of ELP4 are associated with language impairment, autism spectrum disorder, and mental retardation. *Hum. Mutat.*, **36**, 842–850.
129. Fadason, T., Ekblad, C., Ingram, J.R., Schierding, W.S. and O'Sullivan, J.M. (2017) Physical interactions and expression quantitative traits loci identify regulatory connections for obesity and type 2 diabetes associated SNPs. *Front. Genet.*, **8**, 150.
130. Delaunay, S., Rapino, F., Tharun, L., Zhou, Z., Heukamp, L., Termaat, M., Shostak, K., Klevernic, I., Florin, A., Desmecht, H. *et al.* (2016) Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. *J. Exp. Med.*, **213**, 2503–2523.

131. Zinshteyn, B. and Gilbert, W.V. (2013) Loss of a conserved tRNA anticodon modification perturbs cellular signaling. *PLoS Genet.*, **9**, e1003675.
132. Shaheen, R., Patel, N., Shamseldin, H., Alzahrani, F., Al-Yamany, R., ALMoisheer, A., Ewida, N., Anazi, S., Alnemer, M., Elsheikh, M. et al. (2016) Accelerating matchmaking of novel dysmorphism syndromes through clinical and genomic characterization of a large cohort. *Genet. Med.*, **18**, 686–695.
133. Shaheen, R., Al-Salam, Z., El-Hattab, A.W. and Alkuraya, F.S. (2016) The syndrome dysmorphic facies, renal agenesis, ambiguous genitalia, microcephaly, polydactyly and lissencephaly (DREAM-PL): Report of two additional patients. *Am. J. Med. Genet. A*, **170**, 3222–3226.
134. Yamada, Y., Yasukochi, Y., Kato, K., Oguri, M., Horibe, H., Fujimaki, T., Takeuchi, I. and Sakuma, J. (2018) Identification of 26 novel loci that confer susceptibility to early-onset coronary artery disease in a Japanese population. *Biomed. Rep.*, **9**, 383–404.
135. Powell, C.A., Kopajtich, R., D'Souza, A.R., Rorbach, J., Kremer, L.S., Husain, R.A., Dallabona, C., Donnini, C., Alston, C.L., Griffin, H. et al. (2015) TRMT5 mutations cause a defect in Post-transcriptional modification of mitochondrial tRNA associated with multiple Respiratory-Chain deficiencies. *Am. J. Hum. Genet.*, **97**, 319–328.
136. Zhou, M., Xue, L., Chen, Y., Li, H., He, Q., Wang, B., Meng, F., Wang, M. and Guan, M.-X. (2018) A hypertension-associated mitochondrial DNA mutation introduces an m1G37 modification into tRNAMet, altering its structure and function. *J. Biol. Chem.*, **293**, 1425–1438.
137. Rodriguez, V., Chen, Y., Elkhahoun, A., Dutra, A., Pak, E. and Chandrasekharappa, S. (2007) Chromosome 8 BAC array comparative genomic hybridization and expression analysis identify amplification and overexpression of TRMT12 in breast cancer. *Genes. Chromosomes Cancer*, **46**, 694–707.
138. Simpson, H.M., Khan, R.Z., Song, C., Sharma, D., Sadashivaiah, K., Furusawa, A., Liu, X., Nagaraj, S., Sengamalay, N., Sadzewicz, L. et al. (2015) Concurrent mutations in ATM and genes associated with common  $\gamma$  chain signaling in peripheral T cell lymphoma. *PLoS One*, **10**, e0141906.
139. Yeon, S.Y., Jo, Y.S., Choi, E.J., Kim, M.S., Yoo, N.J. and Lee, S.H. (2018) Frameshift mutations in repeat sequences of ANK3, HACD4, TCPI0L, TP53BP1, MFN1, LCMT2, RNMT, TRMT6, METTL8 and METTL16 genes in colon cancers. *Pathol. Oncol. Res.*, **24**, 617–622.
140. Huang, B., Zhai, W., Hu, G., Huang, C., Xie, T., Zhang, J. and Xu, Y. (2016) MicroRNA-206 acts as a tumor suppressor in bladder cancer via targeting YRDC. *Am. J. Transl. Res.*, **8**, 4705–4715.
141. Hyun, H.S., Kim, S.H., Park, E., Cho, M.H., Kang, H.G., Lee, H.S., Miyake, N., Matsumoto, N., Tsukaguchi, H. and Cheong, H. II (2018) A familial case of Galloway-Mowat syndrome due to a novel TP53RK mutation: a case report. *BMC Med. Genet.*, **19**, 131.
142. Hideshima, T., Cottini, F., Nozawa, Y., Seo, H.-S., Ohguchi, H., Samur, M.K., Cirstea, D., Mimura, N., Iwasawa, Y., Richardson, P.G. et al. (2017) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. *Blood*, **129**, 1308–1319.
143. Igoillo-Esteve, M., Genin, A., Lambert, N., Désir, J., Pirson, I., Abdulkarim, B., Simonis, N., Drielsma, A., Marselli, L., Marchetti, P. et al. (2013) tRNA methyltransferase homolog gene TRMT10A mutation in young onset diabetes and primary microcephaly in humans. *PLoS Genet.*, **9**, e1003888.
144. Ismail, N.A., Ragab, S., Abd El Dayem, S.M., Baky, A.N.A.E., Hamed, M., Ahmed Kamel, S. and Adel El Halim, D. (2018) Implication of CDKAL1 single-nucleotide polymorphism rs 9465871 in obese and non-obese Egyptian children. *Med. J. Malaysia*, **73**, 286–290.
145. Yang, X.-X., He, X.-Q., Li, F.-X., Wu, Y.-S., Gao, Y. and Li, M. (2012) Risk-association of DNA methyltransferases polymorphisms with gastric cancer in the Southern Chinese population. *Int. J. Mol. Sci.*, **13**, 8364–8378.
146. Chowdhury, S., Hobbs, C.A., MacLeod, S.L., Cleves, M.A., Melnyk, S., James, S.J., Hu, P. and Erickson, S.W. (2012) Associations between maternal genotypes and metabolites implicated in congenital heart defects. *Mol. Genet. Metab.*, **107**, 596–604.
147. Shaheen, R., Han, L., Faqeih, E., Ewida, N., Alobeid, E., Phizicky, E.M. and Alkuraya, F.S. (2016) A homozygous truncating mutation in PUS3 expands the role of tRNA modification in normal cognition. *Hum. Genet.*, **135**, 707–713.
148. Abdelrahman, H.A., Al-Shamsi, A.M., Ali, B.R. and Al-Gazali, L. (2018) A null variant in PUS3 confirms its involvement in intellectual disability and further delineates the associated neurodevelopmental disease. *Clin. Genet.*, **94**, 586–587.
149. Leschziner, G.D., Coffey, A.J., Andrew, T., Gregorio, S.P., Dias-Neto, E., Calafato, M., Bentley, D.R., Kinton, L., Sander, J.W. and Johnson, M.R. (2011) Q8IYL2 is a candidate gene for the familial epilepsy syndrome of Partial Epilepsy with Pericentral Spikes (PEPS). *Epilepsy Res.*, **96**, 109–115.
150. Hadjigeorgiou, G.M., Kountra, P.-M., Koutsis, G., Tsimourtou, V., Siokas, V., Dardioti, M., Rikos, D., Marogianni, C., Aloizou, A.-M., Karadima, G. et al. (2018) Replication study of GWAS risk loci in Greek multiple sclerosis patients. *Neurol. Sci.*, doi:10.1007/s10072-018-3617-6.
151. Shaheen, R., Abdel-Salam, G.M.H., Guy, M.P., Alomar, R., Abdel-Hamid, M.S., Affi, H.H., Ismail, S.I., Emam, B.A., Phizicky, E.M. and Alkuraya, F.S. (2015) Mutation in WDR4 impairs tRNA m(7)G46 methylation and causes a distinct form of microcephalic primordial dwarfism. *Genome Biol.*, **16**, 210.
152. Hicks, D.G., Janarthanan, B.R., Vardarajan, R., Kulkarni, S.A., Khoury, T., Dim, D., Budd, G.T., Yoder, B.J., Tubbs, R., Schreyer, M.T. et al. (2010) The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. *BMC Cancer*, **10**, 108.
153. Festen, E.A.M., Goyette, P., Green, T., Boucher, G., Beauchamp, C., Trynka, G., Dubois, P.C., Lagacé, C., Stokkers, P.C.F., Hommes, D.W. et al. (2011) A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Crohn's disease and celiac disease. *PLoS Genet.*, **7**, e1001283.
154. Shi, L., Yang, X.-M., Tang, D.-D., Liu, G., Yuan, P., Yang, Y., Chang, L.-S., Zhang, L.-R. and Song, D.-K. (2015) Expression and significance of m1A transmethyase, hTrm6p/hTrm61p and its related gene hTrm6/hTrm61 in bladder urothelial carcinoma. *Am. J. Cancer Res.*, **5**, 2169–2179.
155. Macari, F., El-Houfi, Y., Boldina, G., Xu, H., Khoury-Hanna, S., Ollier, J., Yazdani, L., Zheng, G., Bièche, I., Legrand, N. et al. (2016) TRM6/61 connects PKC $\alpha$  with translational control through tRNAi(Met) stabilization: impact on tumorigenesis. *Oncogene*, **35**, 1785–1796.
156. Li, C., Wang, S., Xing, Z., Lin, A., Liang, K., Song, J., Hu, Q., Yao, J., Chen, Z., Park, P.K. et al. (2017) A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. *Nat. Cell Biol.*, **19**, 106–119.
157. Metodiev, M.D., Thompson, K., Alston, C.L., Morris, A.A.M., He, L., Assouline, Z., Rio, M., Bahi-Buisson, N., Pyle, A., Griffin, H. et al. (2016) Recessive mutations in TRMT10C cause defects in mitochondrial RNA processing and multiple respiratory chain deficiencies. *Am. J. Hum. Genet.*, **98**, 993–1000.
158. Oerum, S., Roovers, M., Leichsenring, M., Acquaviva-Bourdain, C., Beermann, F., Gemperle-Britschgi, C., Fouilhoux, A., Korwitz-Reichelt, A., Bailey, H.J., Droogmans, L. et al. (2017) Novel patient missense mutations in the HSD17B10 gene affect dehydrogenase and mitochondrial tRNA modification functions of the encoded protein. *Biochim. Biophys. Acta Mol. Basis Dis.*, **1863**, 3294–3302.
159. Blaesius, K., Abbasi, A.A., Tahir, T.H., Tietze, A., Picker-Minh, S., Ali, G., Farooq, S., Hu, H., Latif, Z., Khan, M.N. et al. (2018) Mutations in the tRNA methyltransferase 1 gene TRMT1 cause congenital microcephaly, isolated inferior vermian hypoplasia and cystic leukomalacia in addition to intellectual disability. *Am. J. Med. Genet. A*, **176**, 2517–2521.
160. Job, B., Bernheim, A., Beau-Faller, M., Camilleri-Broët, S., Girard, P., Hofman, P., Mazières, J., Toujani, S., Lacroix, L., Laffaire, J. et al. (2010) Genomic aberrations in lung adenocarcinoma in never smokers. *PLoS One*, **5**, e15145.
161. Cheng, J.X., Chen, L., Li, Y., Cloe, A., Yue, M., Wei, J., Watanabe, K.A., Shammo, J.M., Anastasi, J., Shen, Q.J. et al. (2018) RNA cytosine methylation and methyltransferases mediate

- chromatin organization and 5-azacytidine response and resistance in leukaemia. *Nat. Commun.*, **9**, 1163.
162. Kopajtich, R., Nicholls, T.J., Rorbach, J., Metodiev, M.D., Freisinger, P., Mandel, H., Vanlander, A., Ghezzi, D., Carrozzo, R., Taylor, R.W. *et al.* (2014) Mutations in GTPBP3 cause a mitochondrial translation defect associated with hypertrophic cardiomyopathy, lactic acidosis, and encephalopathy. *Am. J. Hum. Genet.*, **95**, 708–720.
  163. Bykhovskaya, Y., Mengesha, E., Wang, D., Yang, H., Estivill, X., Shohat, R. and Fischel-Ghodsian, N. (2004) Phenotype of non-syndromic deafness associated with the mitochondrial A1555G mutation is modulated by mitochondrial RNA modifying enzymes MTO1 and GTPBP3. *Mol. Genet. Metab.*, **83**, 199–206.
  164. Li, X., Li, R., Lin, X. and Guan, M.-X. (2002) Isolation and characterization of the putative nuclear modifier gene MTO1 involved in the pathogenesis of deafness-associated mitochondrial 12 S rRNA A1555G mutation. *J. Biol. Chem.*, **277**, 27256–27264.
  165. Taylor, R.W., Pyle, A., Griffin, H., Blakely, E.L., Duff, J., He, L., Smertenko, T., Alston, C.L., Neeve, V.C., Best, A. *et al.* (2014) Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. *JAMA*, **312**, 68–77.
  166. Donner, I., Katainen, R., Kaasinen, E., Aavikko, M., Sipilä, L.J., Pukkala, E. and Aaltonen, L.A. (2018) Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma. *Fam. Cancer*, doi:10.1007/s10689-018-0099-x.
  167. Lin, H., Miyauchi, K., Harada, T., Okita, R., Takeshita, E., Komaki, H., Fujioka, K., Yagasaki, H., Goto, Y.-I., Yanaka, K. *et al.* (2018) CO2-sensitive tRNA modification associated with human mitochondrial disease. *Nat. Commun.*, **9**, 1875.
  168. Kernohan, K.D., Dymont, D.A., Pupavac, M., Cramer, Z., McBride, A., Bernard, G., Straub, I., Tetreault, M., Hartley, T., Huang, L. *et al.* (2017) Matchmaking facilitates the diagnosis of an autosomal-recessive mitochondrial disease caused by biallelic mutation of the tRNA isopentenyltransferase (TRIT1) gene. *Hum. Mutat.*, **38**, 511–516.
  169. Xiong, J., Wang, Y., Gu, Y., Xue, Y., Dang, L. and Li, Y. (2018) CDK5RAP1 targeting NF- $\kappa$ B signaling pathway in human malignant melanoma A375 cell apoptosis. *Oncol. Lett.*, **15**, 4767–4774.
  170. Khan, M.A., Rafiq, M.A., Noor, A., Hussain, S., Flores, J. V., Rupp, V., Vincent, A.K., Malli, R., Ali, G., Khan, F.S. *et al.* (2012) Mutation in NSUN2, which encodes an RNA methyltransferase, causes autosomal-recessive intellectual disability. *Am. J. Hum. Genet.*, **90**, 856–863.
  171. Frye, M., Dragoni, I., Chin, S.-F., Spiteri, I., Kurowski, A., Provenzano, E., Green, A., Ellis, I.O., Grimmer, D., Teschendorff, A. *et al.* (2010) Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. *Cancer Lett.*, **289**, 71–80.
  172. Abbasi-Moheb, L., Mertel, S., Gonsior, M., Nouri-Vahid, L., Kahrizi, K., Cirak, S., Wiczorek, D., Motazacker, M.M., Esmaeeli-Nieh, S., Cremer, K. *et al.* (2012) Mutations in NSUN2 cause autosomal-recessive intellectual disability. *Am. J. Hum. Genet.*, **90**, 847–855.
  173. Sekar, S., McDonald, J., Cuyugan, L., Aldrich, J., Kurdoglu, A., Adkins, J., Serrano, G., Beach, T.G., Craig, D.W., Valla, J. *et al.* (2015) Alzheimer's disease is associated with altered expression of genes involved in immune response and mitochondrial processes in astrocytes. *Neurobiol. Aging*, **36**, 583–591.
  174. Couch, F.J., Kuchenbaecker, K.B., Michailidou, K., Mendoza-Fandino, G.A., Nord, S., Lilyquist, J., Olswold, C., Hallberg, E., Agata, S., Ahsan, M.S., Tala, S. Al, Alhashem, A., Softah, A., Al-Owain, M. *et al.* (2018) Genomic and phenotypic delineation of congenital microcephaly. *Genet. Med.*, doi:10.1038/s41436-018-0140-3.
  175. Shaheen, R., Maddirevula, S., Ewida, N., Alsahli, S., Abdel-Salam, G.M.H., Zaki, M.S., Tala, S. Al, Alhashem, A., Softah, A., Al-Owain, M. *et al.* (2018) Genomic and phenotypic delineation of congenital microcephaly. *Genet. Med.*, doi:10.1038/s41436-018-0140-3.
  176. Edvardson, S., Elbaz-Alon, Y., Jalas, C., Matlock, A., Patel, K., Labbé, K., Shaag, A., Jackman, J.E. and Elpeleg, O. (2016) A mutation in the THG1L gene in a family with cerebellar ataxia and developmental delay. *Neurogenetics*, **17**, 219–225.
  177. Yew, T.W., McCreight, L., Colclough, K., Ellard, S. and Pearson, E.R. (2016) tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy. *Diabet. Med.*, **33**, e21–e25.
  178. Zung, A., Kori, M., Burundukov, E., Ben-Yosef, T., Tatoor, Y. and Granot, E. (2015) Homozygous deletion of TRMT10A as part of a contiguous gene deletion in a syndrome of failure to thrive, delayed puberty, intellectual disability and diabetes mellitus. *Am. J. Med. Genet. A*, **167A**, 3167–3173.
  179. Narayanan, M., Ramsey, K., Grebe, T., Schrauwen, I., Szlinger, S., Huentelman, M., Craig, D., Narayanan, V. and C4RCD Research Group (2015) Case Report: Compound heterozygous nonsense mutations in TRMT10A are associated with microcephaly, delayed development, and periventricular white matter hyperintensities [version 1; referees: 2 approved]. *F1000Research*, **4**, 912.
  180. Gillis, D., Krishnamohan, A., Yaacov, B., Shaag, A., Jackman, J.E. and Elpeleg, O. (2014) TRMT10A dysfunction is associated with abnormalities in glucose homeostasis, short stature and microcephaly. *J. Med. Genet.*, **51**, 581–586.
  181. Zhang, X., Liu, J., Yan, S., Huang, K., Bai, Y. and Zheng, S. (2015) High expression of N-acetyltransferase 10: a novel independent prognostic marker of worse outcome in patients with hepatocellular carcinoma. *Int. J. Clin. Exp. Pathol.*, **8**, 14765–14771.
  182. Ma, R., Chen, J., Jiang, S., Lin, S., Zhang, X. and Liang, X. (2016) Up regulation of NAT10 promotes metastasis of hepatocellular carcinoma cells through epithelial-to-mesenchymal transition. *Am. J. Transl. Res.*, **8**, 4215–4223.
  183. Patton, J.R., Bykhovskaya, Y., Mengesha, E., Bertolotto, C. and Fischel-Ghodsian, N. (2005) Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. *J. Biol. Chem.*, **280**, 19823–19828.
  184. Fernandez-Vizarra, E., Berardinelli, A., Valente, L., Tiranti, V. and Zeviani, M. (2007) Nonsense mutation in pseudouridylylase synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA). *J. Med. Genet.*, **44**, 173–180.
  185. El-Hattab, A.W., Saleh, M.A., Hashem, A., Al-Owain, M., Asmari, A. Al, Rabei, H., Abdelraouf, H., Hashem, M., Alazami, A.M., Patel, N. *et al.* (2016) ADAT3-related intellectual disability: Further delineation of the phenotype. *Am. J. Med. Genet. A*, **170A**, 1142–1147.
  186. Sharkia, R., Zalan, A., Jabareen-Masri, A., Zahalka, H. and Mahajnah, M. (2018) A new case confirming and expanding the phenotype spectrum of ADAT3-related intellectual disability syndrome. *Eur. J. Med. Genet.*, **S1769-7212**, 30574–30583.
  187. Salehi Chaleshtori, A.R., Miyake, N., Ahmadvand, M., Bashti, O., Matsumoto, N. and Noruzinia, M. (2018) A novel 8-bp duplication in ADAT3 causes mild intellectual disability. *Hum. genome Var.*, **5**, 7.
  188. Bonnet, C., Grégoire, M.J., Brochet, K., Raffo, E., Leheup, B. and Jonveaux, P. (2006) Pure de-novo 5 Mb duplication at Xp11.22-p11.23 in a male: phenotypic and molecular characterization. *J. Hum. Genet.*, **51**, 815–821.
  189. Fahiminiya, S., Almurieki, M., Nawaz, Z., Staffa, A., Lepage, P., Ali, R., Hashim, L., Schwartzentruber, J., Abu Khadija, K., Zaineddin, S. *et al.* (2014) Whole exome sequencing unravels disease-causing genes in consanguineous families in Qatar. *Clin. Genet.*, **86**, 134–141.
  190. Anderson, S.L., Coli, R., Daly, I.W., Kichula, E.A., Rork, M.J., Volpi, S.A., Ekstein, J. and Rubin, B.Y. (2001) Familial dysautonomia is caused by mutations of the IKAP gene. *Am. J. Hum. Genet.*, **68**, 753–758.
  191. Bento-Abreu, A., Jager, G., Swinnen, B., Rué, L., Hendrickx, S., Jones, A., Staats, K.A., Taes, I., Eykens, C., Nonneman, A. *et al.* (2018) Elongator subunit 3 (ELP3) modifies ALS through tRNA modification. *Hum. Mol. Genet.*, **27**, 1276–1289.
  192. Ladang, A., Rapino, F., Heukamp, L.C., Tharun, L., Shostak, K., Hermand, D., Delaunay, S., Klevernic, I., Jiang, Z., Jacques, N. *et al.* (2015) ELP3 drives Wnt-dependent tumor initiation and regeneration in the intestine. *J. Exp. Med.*, **212**, 2057–2075.
  193. Belalcazar, L.M., Papandonatos, G.D., McCaffery, J.M., Peter, I., Pajewski, N.M., Erar, B., Allred, N.D., Balasubramanyam, A., Bowden, D.W., Brautbar, A. *et al.* (2015) A common variant in the CLDN7/ELP5 locus predicts adiponectin change with lifestyle

- intervention and improved fitness in obese individuals with diabetes. *Physiol. Genomics*, **47**, 215–224.
194. Close, P., Gillard, M., Ladang, A., Jiang, Z., Papuga, J., Hawkes, N., Nguyen, L., Chapelle, J.-P., Bouillenne, F., Svejstrup, J. *et al.* (2012) DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator. *J. Biol. Chem.*, **287**, 32535–32545.
  195. Braun, D.A., Rao, J., Mollet, G., Schapiro, D., Daugeron, M.-C., Tan, W., Gribouval, O., Boyer, O., Revy, P., Jobst-Schwan, T. *et al.* (2017) Mutations in KEOPS-complex genes cause nephrotic syndrome with primary microcephaly. *Nat. Genet.*, **49**, 1529–1538.
  196. Wang, P.Z.T., Prasad, C., Rodriguez Cuellar, C.I. and Filler, G. (2018) Nephrological and urological complications of homozygous c.974G>A (p.Arg325Gln) OSGEP mutations. *Pediatr. Nephrol.*, **33**, 2201–2204.
  197. Tang, X., Hobbs, C.A., Cleves, M.A., Erickson, S.W., MacLeod, S.L., Malik, S. and National Birth Defects Prevention Study (2015) Genetic variation affects congenital heart defect susceptibility in offspring exposed to maternal tobacco use. *Birth Defects Res. A. Clin. Mol. Teratol.*, **103**, 834–842.
  198. Park, S., Liu, M. and Kang, S. (2018) Alcohol Intake Interacts with CDKAL1, HHEX, and OAS3 genetic variants, associated with the risk of type 2 diabetes by lowering insulin secretion in Korean adults. *Alcohol. Clin. Exp. Res.*, **42**, 2326–2336.
  199. Nfor, O.N., Wu, M.-F., Lee, C.-T., Wang, L., Liu, W.-H., Tantoh, D.M., Hsu, S.-Y., Lee, K.-J., Ho, C.-C., Debnath, T. *et al.* (2018) Body mass index modulates the association between CDKAL1 rs10946398 variant and type 2 diabetes among Taiwanese women. *Sci. Rep.*, **8**, 13235.
  200. Alcina, A., Fedetz, M., Fernández, O., Saiz, A., Izquierdo, G., Lucas, M., Leyva, L., García-León, J.-A., Abad-Grau, M.D.M., Alloza, I. *et al.* (2013) Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. *J. Med. Genet.*, **50**, 25–33.
  201. Wikman, H., Nymark, P., Väyrynen, A., Jarmalaite, S., Kallioniemi, A., Salmenkivi, K., Vainio-Siukola, K., Husgafvel-Pursiainen, K., Knuutila, S., Wolf, M. *et al.* (2005) CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. *Genes Chromosomes Cancer*, **42**, 193–199.
  202. Trimouille, A., Lasseaux, E., Barat, P., Deiller, C., Drunat, S., Rooryck, C., Arveiler, B. and Lacombe, D. (2018) Further delineation of the phenotype caused by biallelic variants in the WDR4 gene. *Clin. Genet.*, **93**, 374–377.
  203. Chen, X., Gao, Y., Yang, L., Wu, B., Dong, X., Liu, B., Lu, Y., Zhou, W. and Wang, H. (2018) Speech and language delay in a patient with WDR4 mutations. *Eur. J. Med. Genet.*, **61**, 468–472.
  204. Braun, D.A., Shril, S., Sinha, A., Schneider, R., Tan, W., Ashraf, S., Hermle, T., Jobst-Schwan, T., Widmeier, E., Majmundar, A.J. *et al.* (2018) Mutations in WDR4 as a new cause of Galloway-Mowat syndrome. *Am. J. Med. Genet. A*, **176**, 2460–2465.
  205. Chen, C.-P., Chern, S.-R., Wu, P.-S., Chen, S.-W., Lai, S.-T., Chuang, T.-Y., Chen, W.-L., Yang, C.-W. and Wang, W. (2018) Prenatal diagnosis of a 3.2-Mb 2p16.1-p15 duplication associated with familial intellectual disability. *Taiwan. J. Obstet. Gynecol.*, **57**, 578–582.
  206. Medrano, L.M., Pascual, V., Bodas, A., López-Palacios, N., Salazar, I., Espino-Paisán, L., González-Pérez, B., Urcelay, E., Mendoza, J.L. and Núñez, C. (2018) Expression patterns common and unique to ulcerative colitis and celiac disease. *Ann. Hum. Genet.*, doi:10.1111/ahg.12293.
  207. He, X.-Y., Isaacs, C. and Yang, S.-Y. (2018) Roles of mitochondrial 17 $\beta$ -Hydroxysteroid dehydrogenase type 10 in Alzheimer's disease. *J. Alzheimers. Dis.*, **62**, 665–673.
  208. Roussel, E., Drolet, M.-C., Lavigne, A.-M., Arsenaault, M. and Couet, J. (2018) Multiple short-chain dehydrogenases/reductases are regulated in pathological cardiac hypertrophy. *FEBS Open Biol.*, **8**, 1624–1635.
  209. Davarniya, B., Hu, H., Kahrizi, K., Musante, L., Fattahi, Z., Hosseini, M., Maqsood, F., Farajollahi, R., Wienker, T.F., Ropers, H.H. *et al.* (2015) The role of a novel TRMT1 gene mutation and rare GRM1 gene defect in intellectual disability in two azeri families. *PLoS One*, **10**, e0129631.
  210. Najmabadi, H., Hu, H., Garshasbi, M., Zemojtet, T., Abedini, S.S., Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P. *et al.* (2011) Deep sequencing reveals 50 novel genes for recessive cognitive disorders. *Nature*, **478**, 57–63.
  211. Meseguer, S., Martínez-Zamora, A., García-Arumí, E., Andreu, A.L. and Armengod, M.-E. (2015) The ROS-sensitive microRNA-9/9\* controls the expression of mitochondrial tRNA-modifying enzymes and is involved in the molecular mechanism of MELAS syndrome. *Hum. Mol. Genet.*, **24**, 167–184.
  212. Li, X. and Guan, M.-X. (2002) A human mitochondrial GTP binding protein related to tRNA modification may modulate phenotypic expression of the deafness-associated mitochondrial 12S rRNA mutation. *Mol. Cell. Biol.*, **22**, 7701–7711.
  213. Murayama, K., Shimura, M., Liu, Z., Okazaki, Y. and Ohtake, A. (2018) Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases. *J. Hum. Genet.*, **64**, 113–125.
  214. Asano, K., Suzuki, T., Saito, A., Wei, F.-Y., Ikeuchi, Y., Numata, T., Tanaka, R., Yamane, Y., Yamamoto, T., Goto, T. *et al.* (2018) Metabolic and chemical regulation of tRNA modification associated with taurine deficiency and human disease. *Nucleic Acids Res.*, **46**, 1565–1583.
  215. Kim, T.W., Kim, B., Kim, J.H., Kang, S., Park, S.-B., Jeong, G., Kang, H.-S. and Kim, S.J. (2013) Nuclear-encoded mitochondrial MTO1 and MRPL41 are regulated in an opposite epigenetic mode based on estrogen receptor status in breast cancer. *BMC Cancer*, **13**, 502.
  216. Ghezzi, D., Baruffini, E., Haack, T.B., Invernizzi, F., Melchionda, L., Dallabona, C., Strom, T.M., Parini, R., Burlina, A.B., Meitinger, T. *et al.* (2012) Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. *Am. J. Hum. Genet.*, **90**, 1079–1087.
  217. Umeda, N., Suzuki, T., Yukawa, M., Ohya, Y., Shindo, H., Watanabe, K. and Suzuki, T. (2005) Mitochondria-specific RNA-modifying enzymes responsible for the biosynthesis of the wobble base in mitochondrial tRNAs. Implications for the molecular pathogenesis of human mitochondrial diseases. *J. Biol. Chem.*, **280**, 1613–1624.
  218. Gaignard, P., Gonzales, E., Ackermann, O., Labrune, P., Correia, I., Therond, P., Jacquemin, E. and Slama, A. (2013) Mitochondrial infantile liver disease due to TRMU gene Mutations: Three new cases. *JIMD Rep.*, **11**, 117–123.
  219. Schara, U., von Kleist-Retzow, J.-C., Lainka, E., Gerner, P., Pyle, A., Smith, P.M., Lochmüller, H., Czermin, B., Abicht, A., Holinski-Feder, E. *et al.* (2011) Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations. *J. Inher. Metab. Dis.*, **34**, 197–201.
  220. Zeharia, A., Shaag, A., Pappo, O., Mager-Heckel, A.-M., Saada, A., Bejat, P., Karicheva, O., Mandel, H., Ofek, N., Segel, R. *et al.* (2009) Acute infantile liver failure due to mutations in the TRMU gene. *Am. J. Hum. Genet.*, **85**, 401–407.
  221. Guan, M.-X., Yan, Q., Li, X., Bykhovskaya, Y., Gallo-Teran, J., Hajek, P., Umeda, N., Zhao, H., Garrido, G., Mengesha, E. *et al.* (2006) Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. *Am. J. Hum. Genet.*, **79**, 291–302.
  222. Khatami, S., Rokni-Zadeh, H., Mohsen-Pour, N., Biglari, A., Changi-Ashtiani, M., Shahrooei, M. and Shahani, T. (2018) Whole exome sequencing identifies both nuclear and mitochondrial variations in an Iranian family with non-syndromic hearing loss. *Mitochondrion*, **S1567-7249**, 30024–30032.
  223. Yue, Z., Li, H.-T., Yang, Y., Hussain, S., Zheng, C.-H., Xia, J. and Chen, Y. (2016) Identification of breast cancer candidate genes using gene co-expression and protein-protein interaction information. *Oncotarget*, **7**, 36092–36100.
  224. Chen, S., Zheng, Z., Tang, J., Lin, X., Wang, X. and Lin, J. (2013) Association of polymorphisms and haplotype in the region of TRIT1, MYCL1 and MFSD2A with the risk and clinicopathological features of gastric cancer in a southeast Chinese population. *Carcinogenesis*, **34**, 1018–1024.
  225. Spinola, M., Galvan, A., Pignatiello, C., Conti, B., Pastorino, U., Nicander, B., Paroni, R. and Dragani, T.A. (2005) Identification and functional characterization of the candidate tumor suppressor gene TRIT1 in human lung cancer. *Oncogene*, **24**, 5502–5509.
  226. Palmer, C.J., Bruckner, R.J., Paulo, J.A., Kazak, L., Long, J.Z., Mina, A.I., Deng, Z., LeClair, K.B., Hall, J.A., Hong, S. *et al.* (2017)



- Cdkal1, a type 2 diabetes susceptibility gene, regulates mitochondrial function in adipose tissue. *Mol. Metab.*, **6**, 1212–1225.
227. Shin, M.-K., Uhm, Y.-K., Lee, J.-H., Kim, S.-K., Chung, J.-H. and Lee, M.-H. Association between CDK5RAP1 polymorphisms and susceptibility to vitiligo in the Korean population. *Eur. J. Dermatol.*, **22**, 495–499.
228. Steinthorsdottir, V., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Jonsdottir, T., Walters, G.B., Styrkarsdottir, U., Gretarsdottir, S., Emilsson, V., Ghosh, S. *et al.* (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nat. Genet.*, **39**, 770–775.
229. Okamoto, M., Hirata, S., Sato, S., Koga, S., Fujii, M., Qi, G., Ogawa, I., Takata, T., Shimamoto, F. and Tatsuka, M. (2012) Frequent increased gene copy number and high protein expression of tRNA (cytosine-5-)-methyltransferase (NSUN2) in human cancers. *DNA Cell Biol.*, **31**, 660–671.
230. Martinez, F.J., Lee, J.H., Lee, J.E., Blanco, S., Nickerson, E., Gabriel, S., Frye, M., Al-Gazali, L. and Gleeson, J.G. (2012) Whole exome sequencing identifies a splicing mutation in NSUN2 as a cause of a Dubowitz-like syndrome. *J. Med. Genet.*, **49**, 380–385.
231. Komara, M., Al-Shamsi, A.M., Ben-Salem, S., Ali, B.R. and Al-Gazali, L. (2015) A novel Single-Nucleotide deletion (c.1020delA) in NSUN2 causes intellectual disability in an emirati child. *J. Mol. Neurosci.*, **57**, 393–399.
232. Yi, J., Gao, R., Chen, Y., Yang, Z., Han, P., Zhang, H., Dou, Y., Liu, W., Wang, W., Du, G. *et al.* (2017) Overexpression of NSUN2 by DNA hypomethylation is associated with metastatic progression in human breast cancer. *Oncotarget*, **8**, 20751–20765.